



OPEN ACCESS

Digenic inheritance in medical genetics

Alejandro A Schäffer

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/jmedgenet-2013-101713>).

Correspondence to

Dr Alejandro A Schäffer,
Computational Biology Branch,
National Center for
Biotechnology Information,
National Institutes of Health,
Department of Health and
Human Services, 8600
Rockville Pike, Bethesda, MD
20894, USA;
schaffer@helix.nih.gov

Received 2 April 2013

Revised 24 May 2013

Accepted 28 May 2013

Published Online First

19 June 2013

ABSTRACT

Digenic inheritance (DI) is the simplest form of inheritance for genetically complex diseases. By contrast with the thousands of reports that mutations in single genes cause human diseases, there are only dozens of human disease phenotypes with evidence for DI in some pedigrees. The advent of high-throughput sequencing (HTS) has made it simpler to identify monogenic disease causes and could similarly simplify proving DI because one can simultaneously find mutations in two genes in the same sample. However, through 2012, I could find only one example of human DI in which HTS was used; in that example, HTS found only the second of the two genes. To explore the gap between expectation and reality, I tried to collect all examples of human DI with a narrow definition and characterise them according to the types of evidence collected, and whether there has been replication. Two strong trends are that knowledge of candidate genes and knowledge of protein–protein interactions (PPIs) have been helpful in most published examples of human DI. By contrast, the positional method of genetic linkage analysis, has been mostly unsuccessful in identifying genes underlying human DI. Based on the empirical data, I suggest that combining HTS with growing networks of established PPIs may expedite future discoveries of human DI and strengthen the evidence for them.

INTRODUCTION

Digenic inheritance (DI) has fascinated geneticists since the early 20th century. In the early decades of studies on genetics, the term ‘epistasis’ was used by some to describe some forms of digenic inheritance,¹ but in recent decades ‘epistasis’ has been used to describe a much broader category of locus–locus interactions in polygenic diseases, including but not limited to interactions of loci identified by genome-wide association studies.² This review is a synthesis of knowledge about digenic inheritance in a narrow sense, not about epistasis in a broad sense.

Defrise-Gussenhoven³ suggested more than 50 years ago that there would be many human disease pedigrees showing reduced penetrance when treated in genetic analysis as monogenic, but that the inheritance could be explained more accurately by a two-locus model. The first prediction came true, but few studies of pedigrees with incomplete penetrance consider two-locus analysis, even though good methods have been developed.^{4–6} In this context, ‘reduced penetrance’ means that while all or almost all affected pedigree members are modelled as having the mutant genotype at the primary locus, one or more relatives with the primary mutant genotype are unaffected; genetic modelling allows for the imperfect correspondence between genotype and phenotype.

The first report of DI in a human disease was in 1994 for retinitis pigmentosa (RP).⁷ This report was convincing because it included data from multiple pedigrees, and the protein products of the two genes had a known interaction. After 1994, there was a trickle of additional DI reports until 2001, which saw prominent reports of human DI in Bardet–Biedl syndrome (BBS),⁸ deafness⁹ and other phenotypes. These discoveries stimulated a trio of influential reviews in 2002–2003.^{10–12} Since 2002, discoveries of human DI have been appearing at a steady pace (see Discussion), but were not reviewed systematically, except for specific diseases, such as deafness¹³ and Hirschprung’s disease.¹⁴

The three reviews and other contemporaneous papers engaged in a lively but inconclusive debate on how to define human DI. Here, I use a narrow, operational definition that inheritance is digenic when the variant genotypes at two loci explain the phenotypes of some patients and their unaffected (or more mildly affected) relatives more clearly than the genotypes at one locus alone. This includes cases where both loci determine who is affected, a substantial change in severity, or a substantial change in age of onset. The definition includes cases in which one locus is the primary locus, and by itself has variable expressivity, as well as cases where the two loci are roughly equal in importance. I generally exclude cases where the inheritance is polygenic with many more than two loci involved. I generally exclude ‘modifier loci’ that have a modest effect on the phenotype and for which the evidence is only statistical.¹⁵ For diseases whose aetiology involves more than two genes, formalisms, such as Bayesian networks, may be needed to describe the role of each gene and its variants in the ‘cause’ of the disease.

In the prominent example of BBS and others in the section on five examples below, a simple deterministic model that explained some pedigrees proved to be too simple for all pedigrees. When large collections of pedigrees are available, probabilistic models that assign higher probabilities to patients who have more mutations will likely fit the collection of data better. The impetus to collect hundreds of patients and fit a statistical genotype–phenotype model comes after initial observations of one or a few pedigrees that fit simpler models of multigenic inheritance. Therefore, this review focuses attention on how to find the initial digenic patients and pedigrees.

Besides the lack of recent reviews, another stimulus for this review is the hypothesis that high-throughput DNA sequencing (HTS) would be an enabling technology to accelerate discoveries of human DI. Because HTS makes it possible to sequence many genes simultaneously, disease-relevant mutations in two genes can be discovered in a single experiment.

To cite: Schäffer AA. *J Med Genet* 2013;50:641–652.

HTS does not solve the problem of deciding which mutations are relevant to the phenotype, and doing so is more difficult when the inheritance is digenic as compared with monogenic.

There has been one recent example of HTS enabling a proof of DI. The disease is facioscapulohumeral muscular dystrophy (FSHD) type 2.¹⁶ The primary locus for both type 1 and type 2 FSHD is *DUX4*, and that had been discovered by pre-HTS methods. In many pedigrees with type 2 FSHD, the penetrance of the *DUX4* variant is incomplete. Therefore, Lemmers *et al*¹⁶ sought a second locus via HTS. They found that heterozygous, rare variants in the gene *SMCHD1* could explain the inheritance pattern in 21/26 individuals in various pedigrees. Patients with a variant at *DUX4* and a variant at *SMCHD1* are mostly affected, while patients with a variant at *DUX4* and wild type at *SMCHD1* are mostly unaffected. *SMCHD1* controls epigenetic marks affecting gene expression, so the basis for the DI is likely to be a protein–DNA interaction between *SMCHD1* and *DUX4*, affecting the expression of *DUX4*.

I could not find any other studies in which HTS has facilitated a discovery of human DI, though a second example was published online after this article was submitted.¹⁷ To investigate why, I started by building a catalogue of human DI examples. Next, I analysed what study designs had been tried. Then, I considered some of the more publicised examples to see if there was anything special about the most replicated cases of human DI. The successes and some not-so-successful examples suggest three lessons that may aid future studies of human DI. In the Discussion, I use an epistemological approach to suggest how HTS and other new technologies may be used to accelerate the pace of future discoveries.

COLLECTION OF EXAMPLES OF HUMAN DIGENIC INHERITANCE

To collect examples of human digenic inheritance, I used previous reviews,^{10–14} Online Mendelian Inheritance in Man (OMIM),¹⁸ PubMed, PubMed Central, and Google Scholar. I used the Citation Index to find more examples and to look for replications and refutations of previous publications. The search ended in January 2013. Some items in early reviews were excluded here because: they were for model organisms; they had been subsequently refuted; the evidence for the second locus looks weak; or the second locus is a modifier locus based primarily on statistical evidence. The collection of references on BBS and other ciliopathies is incomplete, since the evidence for and against DI in those disorders has been extensively explored elsewhere.^{10 12 19 20}

All DI examples are collected in online supplementary table S1, along with two studies at the bottom in which possible DI of a multisystem syndrome turned out to be two different diseases. The examples that are not primarily replication studies are presented succinctly in table 1. For DI examples that have been repeatedly replicated, such as *CDKN2A* and *MC1R* in melanoma susceptibility,²¹ only a few replicating papers are included. The inheritance at each locus can be usually described as autosomal dominant (AD), autosomal recessive (AR), or X-linked recessive (XLR). The main exception is triallelic inheritance, explained below, in the subsection on BBS. Other examples of possible triallelic inheritance can be found in online supplementary table S1 by searching the two columns titled ‘Inh.’ for the word ‘triallelic’.

Ideal evidence for DI would include identification of the two genes involved in multiple pedigrees with multiple affected individuals in at least one pedigree. The evidence is strengthened by a comparison of the phenotypes of individuals having the mutations in both genes to the phenotypes of individuals with only one gene or the other gene mutated. Ideal digenic pedigrees

may be hard to find. Therefore, in a few cases, such as Long QT syndrome (LQTS), the evidence accumulates over multiple studies.^{22–26} Various studies suggested DI based on one or a few patients without pedigree evidence. To evaluate whether genetic linkage analysis (GLA) is useful to find DI, I included studies in which strong evidence of two loci was found by linkage analysis, without requiring that the two genes have been found.

The data about each study include: the loci and genes, whether there was pedigree evidence, whether the study was replicated later, had internal replication only, or mostly replicated a prior study (see online supplementary table S1). Two additional useful pieces of information are: whether the loci are genetically linked, and whether there is any functional relationship between the two genes or their protein products. The functional relationships could be: protein–protein interaction (PPI), protein–DNA interaction, or being on a shared pathway without a known direct interaction. The importance of whether the loci are linked, and whether the genes have any interaction, is considered in the section entitled: ‘Three lessons for future studies of human digenic inheritance’.

COMMONLY USED STUDY DESIGNS

Two experimental study designs predominate among the reported cases of human digenic inheritance. These are illustrated abstractly in figure 1. I consider one alternative design in this section and another alternative design in the Discussion.

The majority of examples in table 1 and almost all examples in which both genes have been identified are based on a candidate gene (CG) design, proceeding as follows:

1. Identify a small set of genes $G = \{g_1, g_2, \dots\}$ that are mutated, or might be mutated, in monogenic forms of some disease, D, that has locus heterogeneity.
2. Use Sanger sequencing to sequence at least two of the genes in G in a set of patients with disease D and perhaps in their relatives.
3. Identify patients with mutations in two genes.

The evidence from the CG study design is more impressive when relatives having only one of the two genes mutated are unaffected or have a different phenotype than the patients with two genes mutated. Additional experiments to identify how the two genes/proteins interact or reproducing the DI in an animal model²⁷ strengthen the evidence.

The CG study design (figure 1A) has been successful, but a limitation is that the genes to sequence must be selected in advance. DI in which mutations in each of the pair of genes lead to no phenotype is nearly impossible to detect by the CG study design.

A second study design, which avoids the need to preselect genes, is based on GLA. The GLA design (figure 1B) proceeds roughly as follows:

1. Identify one or more pedigrees with cases of a disease and preferably with evidence of reduced penetrance (eg, likely dominant inheritance in which some obligate mutation carriers are unaffected).
2. Genotype markers across the genome.
3. Analyse for linkage either one locus at a time or using two-locus linkage analysis.
4. (Ideal but rarely completed) By sequencing, find mutations in one gene in each of the linkage regions.

I could not find a single example where the sequencing step (4) was completed successfully to identify both genes on *different* chromosomes. Rotor syndrome is one recent successful example of GLA in which the two genes are tightly linked, so linkage analysis was done as if the disease is monogenic.²⁸ Also, when the first gene is known, then linkage analysis to find the second locus can

Table 1 Original, non-overlapping findings of human digenic inheritance

Disease	Gene/locus1	Gene/locus2	Replication	Reference(s)
Long QT syndrome (LQTS)	<i>KCNH2</i> /7q	<i>KCNQ1</i> /11p	Yes	22
LQTS	various LQT genes	various LQT genes	Yes	23–26
Deafness	<i>GJB2</i> /13q	<i>GJB6</i> /13q	DNA level	9
Deafness	<i>TECTA</i> /11q	1p	No	30 31
Pendred syndrome/deafness	<i>SLC26A4</i> /7q	<i>FOXI1</i> /5q	No	87
Deafness suppression	1q	4q	No	72
Deafness	<i>CDH23</i> /10q	<i>ATP2B2</i> /3p	Partial	49
Usher syndrome	<i>MYO7A</i> /11q	3q	No	88
Usher syndrome	<i>CDH23</i> /10q	<i>PCDH15</i> /10q	Yes	27
Usher syndrome	<i>PDZD7</i> /10q	<i>GPR98</i> /5q	Internal	89
Bartter's syndrome (antenatal w/deafness)	<i>CLCNKA</i> /1p	<i>CLCNKB</i> /1p	Yes	90
Bardet–Biedl syndrome	<i>BBS2</i> /16q	various BBS loci	Yes	8
Bardet–Biedl syndrome	<i>BBS4</i> /15q	various BBS genes	Yes	61
Bardet–Biedl syndrome	<i>BBS1</i> /11q	various BBS genes	Yes	62
Joubert syndrome (+ciliopathies)	<i>CEP41</i> /7q	various genes	No	65
Leber's congenital amaurosis(+ciliopathies)	<i>CEP290</i> /12q	<i>MKKS/BBS6</i> /20p	Internal	66
Short-rib polydactyly (ciliopathy)	<i>NEK1</i> /4q	<i>DYNC2H1</i> /11q	No	67
Nephrotic syndrome	<i>NPHS1</i> /19q	<i>NPHS2</i> /1q	Yes	68
Hypogonadotropic hypogonadism	<i>PROKR2</i> /20p	<i>KAL1</i> /Xp	Yes	69
Hypogonadotropic hypogonadism	<i>FGFR1</i> /8p	<i>NSMF</i> /9q	Yes	70
Hypogonadotropic hypogonadism	<i>FGF8-related</i>	<i>FGF8-related</i>	Internal	71
Hypogonadotropic hypo. (syndromic)	<i>RNF216</i> /7p	<i>OTUD4</i> /4q	No	17
Hirschsprung disease	<i>RET</i> /10q	<i>EDNRB</i> /13q	Yes	91
Parkinson's disease	<i>PARK7</i> /1p	<i>PINK1</i> /1p	No	92
Retinitis pigmentosa	<i>PRPH2</i> /6p	<i>ROM1</i> /11q	Internal	7
Glaucoma (earlier onset)	<i>MYOC</i> /1q	<i>CYP11B</i> /2p	Yes	93
Waardenburg syndrome/albinism	<i>MITF</i> /3p	<i>TYR</i> /11q	Partial	94
Oculocutaneous albinism (OCA)	<i>TYR</i> /11q	<i>OCA2</i> /15q	Partial	95
Junctional epidermolysis bullosa	<i>COL17A1</i> /10q	<i>LAMB3</i> /1q	No	96
Disfibrinogenemia (slow clotting)	<i>FGA</i> /4q	<i>FGG</i> /4q	No	97
Polycystic kidney disease	<i>PKD1</i> /16p	<i>PKD2</i> /4q	No	98
Holoprosencephaly	<i>SHH</i> /7q	<i>TGIF1</i> /18p	Internal	11
Familial hypercholest. suppression	<i>LDLR</i> /19p	13q	No	73
Cystinuria	<i>SLC3A1</i> /2p	<i>SLC7A9</i> /19q	Yes	99
Hyperinsulinemia	<i>PPARG</i> /3p	<i>PPP1R3A</i> /7q	No	100
Hypercholanemia	<i>TJP2</i> /9q	<i>BAAT</i> /9q	No	79
Pheochromocytoma	<i>TMEM127</i> /2q	16p	No	32 33
Familial exudative vitreoretinopathy	<i>FZD4</i> /11q	<i>F5</i> /1q	No	101
Factor VIII thromboembolism	5q	11q	No	102
PMP22-related neuropathies	<i>PMP22</i> /17p	various genes	Partial	103 104
Charcot-Marie-Tooth disease (non-PMP22)	<i>MFN2</i> /1p	<i>GDAP1</i> /8q	No	105
Emery-Dreifuss muscular dystrophy	<i>LMNA</i> /1q	<i>EMD</i> /Xq	Yes	106
Porphyria (acute)	various genes	<i>HFE</i> /6p	Pathway level	107
Porphyria (acute)	<i>UROD</i> /1p	<i>HMBS</i> /11q	Pathway level	108
Porphyria (acute)	<i>CPOX</i> /3q	<i>ALAD</i> /9q	Pathway level	109
Epilepsy w/febrile seizures	1q	18q	No	110
Hemochromatosis	<i>HFE</i> /6p	<i>HAMP</i> /19q	No	111
Progressive external ophthalmoplegia	<i>C10orf2</i> /10q	<i>POLG</i> /15q	No	112
Epilepsy w/febrile seizures	<i>SCN1A</i> /2q	<i>SCN2A</i> /2q	No	113
Photosensitivity in epilepsy	7q	16p	No	114
Split-hand/foot malformation	1q	6q	No	115
Iminoglycinuria	<i>SLC36A2</i> /5q	<i>SLC6A20</i> /3p	Internal	116
Keratoconus	1p	8q	No	117
Limb-girdle muscular dystrophy	<i>SGCB</i> /4q	<i>SGCD</i> /5q	No	118
Ullrich congenital muscular dystrophy	<i>COL6A1</i> /21q	<i>COL6A2</i> /21q	No	119
Pseudoxanthoma elasticum	<i>ABCC6</i> /16p	<i>GGCX</i> /2p	No	120
Hereditary motor neuropathy	<i>DSCL2</i> /11q	16p	No	121
Cleft lip	1q	2p	No	122
Fuchs corneal dystrophy	<i>ZEB1</i> /10p	9p	No	29

Continued

Table 1 Continued

Disease	Gene/locus1	Gene/locus2	Replication	Reference(s)
Axenfeld–Rieger syndrome	<i>PITX2</i> /4q	<i>FOXC1</i> /6p	No	123
Colorectal cancer	<i>MUTYH</i> /1p	<i>OGG1</i> /3p	No	124
Rotor syndrome (hyperbilirubinemia)	<i>SLCO1B1</i> /12p	<i>SLCO1B3</i> /12p	Internal	28
Dent's disease	<i>CLCN5</i> /Xp	<i>OCRL</i> /Xq	No	78
Facioscapulohumeral musc. dystrophy	<i>DUX4</i> /4q	<i>SMCHD1</i> /18p	Internal	16
Epidermolysis bullosa simplex	<i>KRT5</i> /12q	<i>KRT14</i> /17q	No	125
Melanoma susceptibility	<i>CDKN2A</i> /9p	<i>MC1R</i> /16q	Yes	21
Hypotrichosis (nonsyndromic)	<i>CDH3</i> /16q	12q	Internal	75

A larger table including more rows with overlapping findings and more columns, such as the mode of inheritance at each locus, can be found in online supplementary table S1. Gene names are currently Hugo Genome Nomenclature Committee-approved names, not necessarily the gene names in the original publication. In some cases, the original study (eg, reference ¹¹) reported multiple pairs of genes, and there is one representative pair in the table. Options for the Replication column (and their meanings) include: Yes (replicated in a later study), Internal (multiple pedigrees in the original study but no later study), Partial (one of the genes participates in some other documented human DI), Pathway level (other genes in the same pathway participate in other documented human DI), DNA level (applies only to *GJB2*/*GJB6* and is explained in the text, No. Examples discussed in the text are put at the top of the Table. The replication references are given in online supplementary table S1.

be done using a monogenic linkage analysis, conditional on the mutation status or haplotype status at the first locus.^{6 29} Two examples where the GLA design succeeded to find the gene at one of two loci are in deafness^{30 31} and pheochromocytomas.^{32 33}

Since GLA has been repeatedly successful in setting up the identification of genes causing monogenic diseases, the failure of the GLA design in DI merits investigation. There exist at least three software packages that can do two-locus linkage analysis: TLINKAGE,³⁴ SUPERLINK³⁵ and GENEHUNTER-TWOLOCUS.⁵ Most of the studies that used two-locus linkage analysis used GENEHUNTER-TWOLOCUS. The mathematical basis for two-locus linkage analysis is that the test statistic, such as a Logarithm of Odds (LOD) score or a NonParametric Linkage (NPL) score typically used to find single disease loci, can be generalised to simultaneous analysis of two disease loci and the genotypes at unlinked marker loci can be combined.⁵ There has been considerable research concerning penetrance models for two-locus linkage analysis, which are needed when the test statistic is the two-locus LOD score.^{1 4 36–39} Thus, the difficulty appears to be due to some unknown gap between theory and reality. One possibility is that human pedigrees with adequate power are hard to find.

The advent of HTS facilitates a third study design (HT):

1. Sequence the exomes or the genomes of a series of patients and their relatives.
2. Identify pairs of genes (g_1 , g_2) that are recurrently mutated in patients.
3. Compare the sequences of g_1 and g_2 in patients and their unaffected relatives.

Since the mutated genes g_1 and g_2 may not be functional candidates, some functional experiments would be needed to show the molecular basis of the DI. A major difficulty in human studies is that one has to sample the relatives who are available. Animal models can mitigate this difficulty. One advantage of the HT design is that one can reconstruct haplotypes to see if multiple nearby mutations are on the same or opposite alleles^{40–42} which is relevant below in the section on three lessons.

I could not find a DI study in which the HT design had identified both genes. Cullinane *et al*⁴³ found two disease-causing mutations in a single experiment, but that patient had two monogenic diseases. In the example of FSHD, the first gene, *DUX4*, had already been found before HTS was applied to find the second gene.¹⁶

FIVE EXAMPLES WITH POSSIBLE REPLICATION

In this section, I summarise the understanding of possible digenic inheritance of five phenotypes where one could consider

that the original claim has been replicated. Some are selected to foreshadow later sections. All five phenotypes occur usually in monogenic forms with locus heterogeneity. Via the CG paradigm, patients with mutations in pairs of the known genes were identified. Surprisingly, I could not find replications of the seminal finding of DI in non-syndromic RP,⁷ though there are many known RP genes. BBS, which is the most studied phenotype with DI does include retinal disease in the phenotype.


Deafness

Similar to RP, deafness is an excellent candidate for DI because there are dozens of known genes that cause monogenic deafness. Additionally, there are animal models of DI for either non-syndromic or syndromic deafness.^{14 44} Considerable information is known about protein complexes that function in the inner ear, and hence, pairs of proteins in these complexes are good candidates for DI. Finally, in some societies, there is assortative mating among deaf individuals or close relatives.⁴⁵ Assortative mating may lead to pedigrees in which multiple deafness-related alleles cosegregate.⁴⁶

Table 1 shows five different entries for deafness, three for Usher syndrome (deafness and blindness), and one for a form of Bartter syndrome (salt wasting) that includes deafness. Perhaps the most compelling among these is the combination of *CDH23* and *PCDH15* causing digenic Usher syndrome because it has been replicated and there is an animal model.^{27 47} However, some of these patients may be better classified as having recessive, monogenic inheritance at *PCDH15*; moreover, *PCDH15* has additional exons that were not sequenced in those patients found to have one mutation in each of *PCDH15* and *CDH23*, and therefore, a second *PCDH15* mutation may have been missed.⁴⁸ An overlapping case where the human DI matches an animal model is the combination of *CDH23* and *ATP2B2* in a single human pedigree.⁴⁹

The most studied example of DI in deafness is the combinations of *GJB2* and *GJB6*^{9 50–52} both of which are also monogenic deafness genes encoding connexins that function in a complex. The evidence for DI among the genes encoding proteins in this connexin complex was strengthened by a report of DI in deafness with mutations in *GJB2* and *GJB3*.⁵³ However, Rodriguez-Paris *et al*^{54 55} have shown that the *GJB2*/*GJB6* case is actually monogenic recessive *GJB2*-caused deafness at the RNA and protein levels. The *GJB6* mutations are deletions that inactivate the second *GJB2* allele, which is nearby on chromosome 13. Further evidence that a regulatory element outside *GJB2* regulates the expression of *GJB2* and *GJB6* is given via allele-specific

Figure 1 Idealised study designs. One of two study designs have been used in almost all published discoveries of human digenic inheritance: (A) An idealised example of the candidate gene design (CG) to search for DI: Displayed is an idealised view of this with four CGs for a certain disease: G₁, G₂, G₃, G₄. In practice, there could any number >1 of genes. Individuals with mutations (mut) in two genes are always affected (black square or circle), but individuals with wild type (wt) sequence for three out of four genes may or may not be affected (variable expressivity of the mutation, white squares or circles). The CG design may include some close relatives. (B) The genetic linkage design: This design is based on studies of one or more pedigrees. Here, m₁ and m₂ could represent either unusual marker haplotypes or mutations in a multigeneration pedigree. Either m₁ or m₂ could show linkage to the disease with reduced penetrance in a similar but larger pedigree, but a two-locus/ digenic model explains the data better. In particular, among individuals carrying exactly one of {m₁, m₂}, some are affected and some are unaffected.



expression assays of a unique deafness-associated haplotype on 13q.⁴⁶ The *GJB2/GJB3* example cannot be similarly refuted because *GJB3* is on chromosome 1.

Long QT syndrome

LQTS is a disease in which patients may suffer cardiac arrhythmias and sudden death. Inheritance is often autosomal dominant, but many pedigrees have incomplete penetrance. LQTS has substantial locus heterogeneity and several pairs of the protein products of LQTS genes interact. The combination of locus heterogeneity, PPIs, and variable expressivity of single gene mutations makes LQTS a good candidate for the model that what looks like reduced penetrance under monogenic inheritance masks DI. The way to follow-up is to compare DNA sequences of affected and unaffected relatives sharing the disease-associated mutation in the

first gene. The follow-up can be done by looking either at a few CGs by Sanger sequencing, or many genes by HTS.

For LQTS, the CG design led to the finding that many LQTS patients have mutations in two of the known genes, such as *KCNQ1/KCNE1*, *KCNQ1/KCNH2*, *KCNH2/KCNE1*, *SCN5A/KCNE1* and other pairs.^{22–26} The penetrance could be increased either by having a second mutation in one LQTS gene or two heterozygous mutations in different genes.^{23 24} All patients with two mutations manifest the disease, often with earlier onset; the distinction between the two-mutation individuals and the one mutation individuals is statistically significant.²³

BBS and other ciliopathies

The phenotype of BBS typically includes six aspects: renal anomalies, polydactyly, obesity, retinal defects, developmental

delay and hypogonadism. Patients are usually diagnosed when at least four symptoms are detected. There is phenotypic overlap between BBS and many other syndromes, including the next two examples. Considering the unusual combination of symptoms, it is surprising that there have been at least 15 genes identified that can cause monogenic BBS with AR inheritance.

When the first BBS genes were found, the function of the encoded proteins was poorly understood. Later studies have shown that these proteins are involved in the formation and function of cilia, primitive sensory organelles present in many cell types.⁵⁶ Primary cilia are non-motile, while other cilia are motile because they have a flexible microtubule configuration.⁵⁶ BBS and overlapping syndromes, such as Joubert syndrome and Meckel-Gruber syndrome, are called 'ciliopathies'.⁵⁶ The phenotypic spectrum of ciliopathies is broad and may include holoprosencephaly,^{57–58} for which DI has been proposed.¹¹ Biochemical studies identified two protein complexes containing seven and three of the 15+ BBS proteins.^{59–60} The protein complexes increase the potential for DI as one could imagine that defects in two of the proteins would be more deleterious than a defect in only one protein.

Before the cilia function and BBS complexes were discovered, Katsanis and colleagues energised the study of BBS and DI by proposing that the inheritance of BBS is *triallelic* in some pedigrees.⁸ Triallelic inheritance means that any combination of three deleterious alleles at two BBS loci, but not three heterozygous mutations at three loci, are sufficient to cause BBS. Triallelic inheritance was also supposed to indicate that there would be individuals with 'only' a biallelic mutation at one BBS locus who would have no phenotype or a milder phenotype. The triallelic inheritance hypothesis has been controversial because few pedigrees in which three mutant alleles are necessary have been reported.²⁰ Early attempts to test the triallelic inheritance hypothesis found that only a small minority of BBS families had exactly two mutant alleles at one locus and a third mutant allele at a second locus.^{61–63} The distribution of mutations is more variable, and the early studies are hard to interpret now because they could only test the subset of BBS genes known at the time of the study. The finding that many BBS patients have mutations in two or more BBS genes has been replicated many times (table 1, see online supplementary table S1). Some BBS patients have as many as five variant alleles in different BBS genes.¹⁹

Some have argued that the large number of BBS genes and high carrier frequencies in some populations suffice to explain the high frequency of patients with two or more BBS genes, without claiming DI.²⁰ The weakness in this argument is that it could be even more applicable to diseases such as blindness, deafness and heart disease that have high locus heterogeneity, but only some specific instances of DI as described above. More problematic to the argument for DI in BBS is that as more patients with mutations in two BBS genes have been discovered, no pattern has emerged to explain which pairs of genes have mutations simultaneously. One could have hypothesised either a 'logical AND' model (the two proteins mutated should be preferentially in the same protein complex) or a 'logical OR' model (the two proteins mutated should be preferentially in different ciliary protein complexes), but neither model fits the BBS mutation data.

The identification of possible DI in BBS has stimulated the search for DI in diseases with phenotypic overlap (see the next two subsections). It has also stimulated the search for modifier genes⁶⁴ and for examples of DI in other ciliopathies.^{65–67}

Nephrotic syndrome

Nephrotic syndrome is a kidney disease in which essential proteins are lost into urine. There is phenotypic similarity with the renal aspect of BBS and other ciliopathies, such as Joubert syndrome. Two of the various monogenic forms of nephrotic syndrome are due to mutations in *NPHS1* on 19q encoding nephrin and *NPHS2* on 1q, encoding podocin. Koziell *et al*⁶⁸ identified three families in which there is triallelic inheritance, and those individuals with three deleterious alleles have a more severe form called 'focal segmental glomerulosclerosis' (FSGS). The two proteins, nephrin and podocin, have a direct interaction. This finding was replicated exactly and in a more general form by finding FSGS patients with three deleterious alleles in several pairs of CGs: *NPHS1/NPHS2*, *CD2AP/NPHS2*, *WT1/NPHSA* (see online supplementary table S1). It is interesting that the initial discovery was made in a kidney disease shortly after Katsanis *et al* proposed triallelic inheritance for BBS. It shows, retrospectively, how one finding of DI might provide impetus for another. The nephrotic syndrome example and the next example suggest the hypothesis that diseases with weak phenotypic similarity to BBS may be good candidates to have DI.

Hypogonadotropic hypogonadism

Hypogonadotropic hypogonadism (HH) is diminished function of the sexual organs associated with deficient secretion or action of the hypothalamic gonadotropin-releasing hormone (GnRH), which controls the pituitary gonadotropins and, thereby, gonadal function. The non-syndromic form is called 'idiopathic HH' (IHH). There is also a widely studied syndromic form (different from BBS) called Kallman syndrome in which HH is combined with anosmia.

The initial report of DI in HH focused on cases with mutations in the ligand-receptor gene pair *PROK2* and *PROKR2*, and also reported one patient with heterozygous mutations in both *PROKR2* and the known gene Kallman syndrome gene *KAL1*.⁶⁹ The pairing of *PROK2* and *PROKR2* is understandable since they form a receptor-ligand pair, but the mechanism of *PROKR2/KAL1* digenic inheritance remains unclear.

Pitteloud *et al*⁷⁰ used the CG design with additional HH genes and found more examples of DI including the gene pairs *FGFR1/NSMF* and *FGFR1/GNRHR*. The general finding of DI in HH has been replicated multiple times (see online supplementary table S1). However, the number of known patients with two genes mutated is small relative to the number of CGs. Thus, as in BBS, no pattern as to which pairs of genes are mutated together is discernible.

While this manuscript was under review, two more studies showing digenic inheritance in HH were published. By a generalisation of the CG design, Miraoui *et al*⁷¹ showed that some non-syndromic HH patients and Kallman syndrome patients have heterozygous mutations in two genes in an FGF8-related pathway. Using HTS, Margolin *et al*¹⁷ found homozygous mutations in *RNF216* and *OTUD4* in three consanguineous siblings with a syndromic form of HH. Using a zebrafish model, they showed that *RNF216* and *OTUD4* have a functional interaction, but they could not find any functional relationship between *RNF216* and *OTUD4* and the genes mutated in non-syndromic HH.

THREE LESSONS FOR FUTURE STUDIES OF HUMAN DIGENIC INHERITANCE

From the catalogue of examples of digenic inheritance, three lessons can be derived to inform future studies. The first two

are subtle enough that they were not explicitly highlighted in previous reviews.^{10–12} The third lesson is not new, but some of its implications have not been mentioned in previous reviews and are explored in the Discussion.

Lesson 1: in the digenic inheritance examples found to date, the variant genotype at the second locus usually increases disease risk

The definition of DI in the Introduction does not specify whether the variant genotype at each locus increases or decreases the disease risk. In the study of monogenic diseases, it is usually understood that the variant genotypes at the disease locus do increase the risk. One can extend this assumption to require that in DI, the locus designated as first also has the property that the variant genotype increases the disease risk. It is possible, however, that the variant genotype at the second locus decreases the disease risk. In some early definitions of epistasis, it was required that the second locus suppresses the (trait-causing) effect of the first locus.¹

Theory differs from practice in the role of the second locus because table 1 shows only three examples of human DI in which the variant genotype at the second locus is definitively suppressive. The first example is deafness in which the first locus is recessive and on 1q, and another recessive locus on 4q cancels the effect of the first.⁷² This example was found by GLA of a large pedigree. The finding has not been replicated, and the genes underlying the two loci have not been identified. The second example is familial hypercholesterolaemia with a primary mutation in the *LDLR* gene on 19p and a recessive locus on 13q that mitigates the effects of the *LDLR* mutation.⁷³ In this example, like the first, the suppressive locus was found by linkage analysis of a single pedigree, and the gene has not been reported, but there is other evidence of a cholesterol-related locus on 13q.⁷⁴ In the third example, the disease is hypotrichosis due primarily to mutations in *CDH3*.⁶⁵ Previously reported cases of hypotrichosis and mutations in *CDH3* are all syndromic. In two pedigrees, a locus on 12p identified by GLA mitigates the hypotrichosis to make it non-syndromic.⁷⁵

Recently, Rachel and colleagues suggested a possible fourth example.⁶⁶ In this example, the two genes, *CEP290* and *MKKS* (also known as *BBS6*), were identified by the CG method and *MKKS* has already been suggested to participate in DI of BBS. The disease is Leber's Congenital Amaurosis (LCA) that is often caused by biallelic mutations in *CEP290*. Biallelic mutations in *CEP290* cause a spectrum of ciliopathies, along which LCA is mild because it affects only the eyes. A surprising percentage of LCA patients had heterozygous mutations in *MKKS*.⁶⁶ Rachel *et al*⁶⁶ proposed that the *MKKS* mutations mitigate the effect the *CEP290* mutations, perhaps 'reducing' the disease severity. This study showed that the two proteins, *CEP290* and *MKKS*, have a direct interaction and constructed a mouse model supporting the DI. The last piece of the proof, which is not reported in the study, would be human pedigrees in which multiple relatives have the same biallelic *CEP290* mutations, and relatives with an *MKKS* mutation have a milder phenotype than relatives without an *MKKS* mutation.

The predominance of cases in which the second locus variant genotype increases risk reflects a bias of the CG design. If more cases of DI are found by HTS, then a greater percentage may have a second locus that reduces the risk. When the variant genotype at the second locus reduces the risk, that variant genotype is going to be found in unaffected or more mildly affected individuals. Therefore, when using the GLA design or HTS or

other designs, it is important to sequence unaffected and mildly affected relatives.

Another approach to identifying a second locus that decreases the risk caused by the variant genotype at the first locus is to compare expression of genes in affected and unaffected relatives with the mutant genotype at the first locus, and this was attempted with some success for spinal muscular atrophy.⁷⁶ One advantage of this approach is that it is unbiased as to which set of relatives will have the unusual expression that is sought. A second advantage of the expression approach is that if the differential expression is found, then that result is closer to a functional experiment than sequence differences would be.⁷⁶ However, the corresponding disadvantage is that it may be difficult to determine whether the expression difference between 'affecteds' and 'unaffecteds' is due to nearby (*in cis*) sequence differences, or due to differences in some other unlinked gene (*in trans*).⁷⁶


Lesson 2: when the two loci are linked, the proof is more complicated

A disproportionate number of the locus pairs in online supplementary table S1 are genetically linked. This includes pairs that are closely linked (*SLCO1B1* and *SLCO1B3* in Rotor syndrome²⁸) and examples with weaker linkage (*LRP5* and *FZD4* in familial exudative vitreoretinopathy⁷⁷). When the two mutations are on the same haplotype, but the linkage is weak, one has a chance to find crossover events between the two genes. If such a crossover is present, then a close relative may have only one of the two gene mutations, and one can compare phenotypes between the individuals having one gene mutated and the individuals having both genes mutated. It is useful to divide the linked situations into four categories by inheritance.


The first category is AR inheritance at both loci (eg, Rotor syndrome). In this category, it is hard to prove that a biallelic mutation in one gene does not suffice to cause the disease. In the case of Rotor syndrome, the proof included multiple pedigrees in which all patients had biallelic mutations in both genes, animal models and identifying other human subjects who had biallelic mutations in only one of the genes and were unaffected.²⁸

The second category is AD or XLR inheritance at both loci with the two mutations on the same haplotype (*in cis*). An XLR example is Dent's disease (*CLCN5* and *OCRL*).⁷⁸ Again, it is difficult to prove that one mutation/gene does not suffice to cause the disease. Another problem for AD inheritance is to evaluate whether all patients have both mutations *in cis*, and if so, why? It should not matter at the protein level whether the mutations are *in cis* or *in trans*, but it does matter for ascertainment. If the mutations are *in cis*, then they can be transmitted over multiple generations, and the inheritance will appear to be AD (figure 2A). One can ascertain large pedigrees that will achieve high LOD scores assuming a single dominant locus. For such pedigrees, HTS should help find the DI because HTS can find both mutated genes on the haplotype in a single experiment.

The third category is AD inheritance at both loci with the two mutations on opposite haplotypes (*in trans*). This differs from the second category because the inheritance will appear to be AR (figure 2B). The affected children would typically all be in one generation. The proof can be easier than in the *in cis* category because, typically, the patient(s) would inherit one mutation from each parent and the parents would be unaffected or have a milder phenotype. The proof can be harder because it is harder to find large pedigrees. If all the paired mutations are *in*



Typical pedigree with linked mutations *in cis*



Typical pedigree with linked mutations *in trans*

Figure 2 Idealised pedigrees for genetically linked loci. Typical pedigrees for digenic inheritance with two linked loci having heterozygous variants either *in cis* or *in trans* have a different structure. (A) When the loci are *in cis*, the inheritance looks like autosomal dominant monogenic inheritance in that pedigree, but high throughput sequencing make it possible to discover both mutations in one experiment. (B) When the loci are *in trans*, the inheritance may appear as autosomal recessive as is seen in deafness with simultaneous *GJB2/GJB6* mutations. The half shading is to indicate that in some cases of digenic inheritance (eg, long QT syndrome) some individuals with one mutation are affected.

trans, one should wonder why no patients with the mutations paired *in cis* can be found. To distinguish the second and third categories, it is important to have parental DNA samples; sequencing parental DNA usually determines whether the mutations are *in cis* or *in trans*.

The case of *GJB2/GJB6* provides a cautionary example of why one should be sceptical if the mutations are always *in trans*. Because there were only two distinct *GJB6* mutations participating in the DI,^{9 50–52} it was plausible that there was a founder effect, and *GJB2* mutations rarely arose on the haplotypes with either *GJB6* deletion. This explanation is incorrect. Each *GJB6* deletion disrupts expression of the apparently wild type *GJB2* allele on the same haplotype.^{54 55} Thus, at the mRNA and protein levels, the deafness is due to monogenic recessive *GJB2* mutations. For gene sequencing, however, it remains useful to consider the inheritance as digenic.

The fourth category is AR at one locus and AD at the other locus. One example in the online supplementary table S1 is hypercholanemia with biallelic mutations in *TJP2* and heterozygous mutations in *BAAT*.⁷⁹ These two genes are weakly linked, so one can consider the data as if they were on distinct chromosomes. This example comes from an isolated population and has

not been replicated in other populations, so genetic drift may have brought the two mutations together.

In a study design that combines GLA with HTS, there would be a possibility of finding two mutated genes in the interval of genetic linkage. In this circumstance, investigators may apply Occam's razor and try to 'pin the blame' on one gene. Examples in table 1 show that this reductionism can be flawed in two different ways. Either the inheritance can be digenic²⁸ or there can be two different diseases in the pedigree each caused by a different gene (eg, cone rod dystrophy and deafness⁸⁰).

Lesson 3: protein-protein interactions are an important type of evidence for digenic inheritance

Many of the entries in online supplementary table S1 for which both genes are known are associated with a direct PPI between the gene products. In some cases, the investigators did the PPI experiments themselves because the interaction was not in a database of PPIs. In principle, having two mutations in interacting proteins could be either a 'double hit' or compensatory.⁸ Lesson 1 is that the double hit situation is much more common than the compensatory situation.

Shoemaker and Panchenko⁸¹ reviewed both *in vitro* methods for finding new PPIs and databases for searching known PPIs. Laboratory methods include: nuclear magnetic resonance, yeast two-hybrid, coimmunoprecipitation, tandem affinity-purification mass spectroscopy (TAP-MS), protein microarrays, fluorescence resonance energy transfer, atomic force microscopy and others. Useful databases of known interactions include Biogrid, MINT, HPRD, STRING, IntAct. A useful resource that collects and organises other database resources is iRefIndex (<http://irefindex.uio.no/wiki/iRefIndex>),⁸² which can be searched using iRefWeb (<http://wodaklab.org/iRefWeb>).⁸³ Two limitations of the iRefIndex data downloads are: (1) they refer to genes by UniProt records, which change over time and (2) when the same interaction is included in various sources, the duplicates are not necessarily consolidated. To address these limitations, Stojmirović and Yu developed a parser *ppiTrim*⁸⁴ whose results identify the genes according to their more stable integer identifiers in NCBI's Entrez gene database. The *ppiTrim* output files are available at <ftp://ftp.ncbi.nih.gov/pub/qmbpmn/ppiTrim/datasets/>.

The files whose names start with 9606 contain human data. One complication in evaluating PPI data is that two proteins may function together in a complex, without a direct interaction.

DISCUSSION

Because HTS sequences many genes in the same experiment, HTS leads frequently to the discovery that a patient has variants in multiple genes that are potentially disease-associated. When the number of patients is small or there is only one pedigree, even sophisticated bioinformatics filtering methods applied to HTS data can leave two or more candidate causal genes and variants.⁸⁵ It may be advisable to consider the possibility of DI in such multicandidate cases, especially if the phenotype is novel. Geneticists using Sanger sequencing (one gene at a time) often stopped looking for mutations even if the genotype–phenotype correlation based on one mutant gene was imperfect, and the finding of an additional mutant gene could explain the observed phenotypes better via DI. In this review, we focused on the distinction between two genes mutated versus one gene mutated because in making that distinction, the methods of proving causality change. The medical geneticist is faced with the general question: Do the variants at both genes together explain the phenotype better than the variant at one gene? Sometimes, the

answer will be ‘yes, because the patient has two monogenic diseases simultaneously’.³⁸ Here, the focus is on cases where the answer is ‘yes, because there is DI of one disease’. I was surprised to find only one study through 2012 where HTS led to discovery of DI.¹⁶ Why so few?

There are three overlapping reasons. First, it is possible that there are not that many cases of human DI. Figure 3 shows the number of new (not replication) reports per year of DI in table 1. The rate of discovery has not increased since 2001. Since the number of monogenic diseases with locus heterogeneity is increasing, and the number of genes contributing to the heterogeneity is increasing, one would expect the number of cases of DI detected by the CG design to be increasing as well, but this is not so. DI is near one end of a spectrum of mechanisms by which combinations of mutations increase disease risk; as more and more of these disease mechanisms are discovered,⁸⁶ attention to DI may be diluted.

A second possibility is that more cases of DI involve PPIs and that should be the starting point to find the genetic evidence. Badano *et al*⁶⁴ pioneered the following PPI design to find cases of DI:

1. Choose g_1 encoding p_1 as a gene of interest in disease, D, based on past discoveries.
2. Use extensive yeast two-hybrid assays to find protein partners of p_1 .
3. For each partner p_i ($i > 1$) encoded by gene g_i , sequence g_i in patients who carry mutations in g_1 .

HTS increases the throughput at step 3 because all the genes can be sequenced in parallel. Techniques more reliable than yeast 2-hybrid assays have been developed to find protein partners.⁸¹ *In silico* databases of known and predicted protein interactions are growing rapidly,⁸¹ making it possible to search among all genes mutated, for pairs of genes encoding protein partners. During my formal literature search, I could not find a second instance in which the PPI design was used to find human DI, but an interesting example in HH was published while the manuscript was being refereed.⁷¹ Some of the later discoveries in online supplementary table S1 could have been made by the PPI design, but were made by the CG design instead.

This suggests a third possible explanation. The complexity of DI transcends the genetics. To construct a compelling proof that the inheritance is digenic rather than monogenic may require a multidisciplinary team that can apply techniques to understand the two genes and proteins specifically and their interaction. If we consider




Figure 3 The pace of digenic inheritance discoveries. Numbers of new (not replication) discoveries of human digenic inheritance published per year during 1994–2012. The numbers were tabulated automatically from a version of table 1 that had an extra column including year of publication.

two of the more exciting findings of 2012,^{16 66} the techniques they used include: double knockout mice, morpholino studies in zebrafish, genotyping and haplotype analysis, expression and RNA interference experiments, methylation studies, splicing experiments, chromatin immunoprecipitation, electron microscopy, yeast two-hybrid experiments, transfection of genes and so on. It is challenging to assemble a scientific team with expertise in all these procedures. The need to assemble these multidisciplinary teams could explain the predominance of the ciliopathies among the studies of DI. Several research groups studying ciliopathies have combined animal models and extensive cell biology experiments in the same study.^{64–66} Once such a team is assembled, there may be other exciting problems to work on instead of identifying new examples of human DI, such as defining the PPIs and biochemical pathways that underlie the DI.^{59 60} In particular, we seem to be closer to a consensus about syllogisms needed to prove PPIs⁸¹ than to a consensus on the syllogisms to give a strong proof of DI. In the case of *GJB2/GJB6* and deafness, a statistical method of proof (high rate of co-occurrence of heterozygous mutations), and evidence for interaction of the two proteins turned out to be incomplete proof.^{46 54 55}

Development of commonly accepted rules of proof in medical genetics has been a slow process. Even in areas such as GLA and genome-wide association studies, in which rigorous statistics can be applied, it took years to establish standards (LOD score thresholds, NPL score thresholds, association p values and q values) of proof. Establishing standards of proof may be at least twice as hard for DI. For example, one concept that was not applied consistently among the studies cited in online supplementary table S1 is that a proof of DI can be strengthened by comparing the genotypes at the two disease-associated loci/genes of the affected individuals to the genotypes of as many unaffected first-degree relatives as possible.

In conclusion, the collection here of known human DI examples provides a basis to identify new examples. Key ingredients to a convincing proof of DI include: evidence of protein–protein or protein–DNA interaction for the two proteins or genes, pedigree data, animal models or very specific functional experiments. HTS is a tool to identify quickly the possible genes in a case of DI, especially when the genes are not obvious candidates, but HTS alone does not provide these three key ingredients to proving the mode of inheritance.

Acknowledgements This research was supported by the Intramural Research Program of the National Institutes of Health (NIH), NLM. Thanks to my NIH colleagues Drs Andrew Cullinane, Thomas Friedman, Marjan Huizing, Anna Panchenko and Aleksandar Stojmirović for useful suggestions. Thanks to Daniel Schäffer (Takoma Park Middle School Magnet Program) for help with the Figures. Thanks to two anonymous referees who made numerous insightful suggestions, including several additional pertinent references, which tangibly improved this review.

Contributors AAS did the research and wrote the manuscript.

Funding National Institutes of Health, Intramural Research Program.

Competing interests None.

Provenance and peer review Commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>

REFERENCES

- 1 Phillips PC. The language of gene interaction. *Genetics* 1998;149:1167–71.
- 2 Cordell HJ. Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. *Hum Mol Genet* 2002;11:2463–8.

- 3 Defrise-Gussenhoven E. Hypothèses de dimérie et de non-pénétrance. *Acta Genet* 1962;12:65–96.
- 4 Strauch K, Fimmers R, Baur MP, Wienker TF. How to model a complex trait. 2. Analysis with two disease loci. *Hum Hered* 2003;56:200–11.
- 5 Dietter J, Spiegel A, an Mey D, Pflug HJ, Al-Kateb H, Hoffmann K, Wienker TF, Strauch K. Efficient two-trait-locus linkage analysis through program optimization and parallelization: application to hypercholesterolemia. *Eur J Hum Genet* 2004;12:542–50.
- 6 Génin E, Feingold J, Clerget-Darpoux F. Identifying modifier genes of monogenic disease: strategies and difficulties. *Hum Genet* 2008;124:357–68.
- 7 Kajiwaru K, Berson EL, Dryja TP. Digenic retinitis pigmentosa due to mutations in the unlinked peripherin/RDS and ROM1 loci. *Science* 1994;264:1604–8.
- 8 Katsanis N, Ansley SJ, Badano JL, Eichers ER, Lewis RA, Hoskins BE, Scambler PJ, Davidson WS, Beales PL, Lupski JR. Triallelic inheritance in Bardet-Biedl syndrome, a Mendelian recessive disorder. *Science* 2001;293:2256–9.
- 9 Lerer I, Sagi M, Ben-Neriah Z, Wang T, Levi H, Abeliovich D. A deletion mutation in GJB6 cooperating with a GJB2 mutation in trans in non-syndromic deafness: a novel founder mutation in Ashkenazi Jews. *Hum Mutat* 2001;18:Mutation in Brief#458 Online.
- 10 Badano JL, Katsanis N. Beyond Mendel: an evolving view of human genetic disease transmission. *Nat Rev Genet* 2002;3:779–89.
- 11 Ming JE, Muenke M. Multiple hits during early embryonic development: digenic diseases and holoprosencephaly. *Am J Hum Genet* 2002;71:1017–32.
- 12 Slavotinek A, Biesecker LG. Genetic modifiers in human development and malformation syndromes, including chaperone proteins. *Hum Mol Genet* 2003;12:R45–50.
- 13 Tam PKH, Garcia-Barceló M. Genetic basis of Hirschsprung's disease. *Pediatr Surg Int* 2009;25:543–58.
- 14 Yan D, Liu X-Z. Modifiers of hearing impairment in humans and mice. *Curr Genomics* 2010;11:269–78.
- 15 Westphal V, Kjaergaard S, Schollen E, Martens K, Grunewald S, Schwartz M, Matthijs G, Freeze HH. A frequent mild mutation in ALG6 may exacerbate the clinical severity of patients with congenital disorder of glycosylation Ia (CDG-Ia) caused by phosphomannomutase deficiency. *Hum Mol Genet* 2002;11:599–604.
- 16 Lemmers RLJF, Tawil R, Petek LM, Balog J, Block GJ, Santen GWE, Amell AM, van der Vliet PJ, Almomeni R, Straasheijm KR, Krom YD, Klooster R, Sun Y, den Dunnen JT, Helmer Q, Donlin-Smith CM, Padberg GW, van Engelen BGM, de Greef JC, Aartsma-Rus AM, Frants RR, de Visser M, Desnuelle C, Sacconi S, Filipova GN, Bakker B, Bamshad MJ, Tapscott SJ, Miller DG, van der Maarel SM. Digenic inheritance of an *SMCHD1* mutation and an *FSHD*-permissive *D4Z4* allele causes facioscapulohumeral muscular dystrophy type 2. *Nat Genet* 2012;44:1370–4.
- 17 Margolin DH, Kousi M, Chan YM, Lim ET, Schmähmann JD, Hadjivassiliou M, Hall JE, Adam I, Dwyer A, Plummer L, Aldrin SV, O'Rourke J, Kirby A, Lage K, Milunsky A, Milunsky JM, Chan J, Hedley-Whyte ET, Daly MJ, Katsanis N, Seminara SB. Ataxia, dementia, and hypogonadotropism caused by disordered ubiquitination. *New Engl J Med* 2013;368:1992–2003.
- 18 McKusick VA. Mendelian Inheritance in Man and its online version, OMIM. *Am J Hum Genet* 2007;80:588–604.
- 19 Billingsley G, Bin J, Fieggen KJ, Duncan JL, Gerth C, Ogata K, Wodak SS, Traboulsi EI, Fishman GA, Paterson A, Chitayat D, Kneuppel T, Millán JM, Mitchell GA, Deveault C, Héon E. Mutations in chaperonin-like BBS genes are a major contributor to disease development in a multiethnic Bardet-Biedl syndrome patient population. *J Med Genet* 2010;47:453–63.
- 20 Hjortshøj TD, Grønskov K, Philip AR, Nishimura DY, Riise R, Sheffield VC, Rosenberg T, Brøndum-Nielsen K. Bardet-Biedl syndrome in Denmark—report of 13 novel sequence variations in six genes. *Hum Mutat* 2010;31:429–36.
- 21 Box NF, Duffy DL, Chen W, Stark M, Martin NG, Sturm RA, Hayward NK. MC1R genotype modifies risk of melanoma in families segregating *CDKN2A* mutations. *Am J Hum Genet* 2001;69:765–73.
- 22 Berthet M, Denjoy I, Donger C, Demay L, Hammoude H, Klug D, Schulze-Bahr E, Richard P, Funke H, Schwartz K, Coumel P, Hainque B, Guicheney P. C-terminal *HERG* mutations: the role of hypokalemia and a *KCNQ1*-associated mutation in cardiac event occurrence. *Circulation* 1999;99:1464–70.
- 23 Westenskow P, Splawski I, Timothy KW, Keating MT, Sanguinetti MC. Compound mutations: a common cause of severe long-QT syndrome. *Circulation* 2004;109:1834–41.
- 24 Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. *Heart Rhythm* 2005;2:507–17.
- 25 Millat G, Chevalier P, Restier-Miron L, Da Costa A, Bouvagnet P, Kugener B, Fayol L, González Armengod C, Oddou B, Chanavat V, Froidefond E, Perraudin R, Rousson R, Rodriguez-Lafresse C. Spectrum of pathogenic mutations and associated polymorphisms in a cohort of 44 unrelated patients with long QT syndrome. *Clin Genet* 2006;70:214–27.
- 26 Vatta M, Ackerman MJ, Ye B, Makielski JC, Ughanzen EE, Taylor EW, Tester DJ, Balijepalli RC, Foell JD, Li Z, Kamp TJ, Towbin JA. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. *Circulation* 2006;114:2104–12.
- 27 Zheng QY, Yan D, Ouyang XM, Du LL, Yu H, Chang B, Johnson KR, Liu XZ. Digenic inheritance of deafness caused by mutations in genes encoding cadherin 23 and protocadherin 15 in mice and humans. *Hum Mol Genet* 2005;14:103–11.
- 28 van de Steeg E, Stránecký V, Hartmannová H, Nosková L, Hřebíček M, Wagenaar E, van Esch A, de Waart DR, Elferink RP Oude, Kenworthy KE, Sticová E, al-Edreesi M, Knisely AS, Kmoch S, Jirsa M, Schinkel AH. Complete *OATP1B1* and *OATP1B3* deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. *J Clin Invest* 2012;122:519–28.
- 29 Riazuddin SA, Zaghoul NA, Al-Saif A, Davey L, Diplas BH, Meadows DN, Eghrari AO, Minear MA, Li Y-J, Klintworth GK, Afshari N, Gregory SG, Gottsch JD, Katsanis N. Missense mutations in *TCF8* cause late-onset Fuchs corneal dystrophy and interact with *FCD4* on chromosome 9p. *Am J Hum Genet* 2010;86:45–53.
- 30 Balciuniene J, Dahl N, Borg E, Samuelsson E, Koisti MJ, Pettersson U, Jazin EE. Evidence for digenic inheritance of non-syndromic hereditary hearing loss in a Swedish family. *Am J Hum Genet* 1998;63:786–93.
- 31 Balciuniene J, Dahl N, Jalonen P, Verhoeven K, Van Camp G, Borg E, Pettersson U, Jazin EE. Alpha-tectorin involvement in hearing disabilities: one gene—two phenotypes. *Hum Genet* 1999;105:211–16.
- 32 Dahia PLM, Hao K, Rogus J, Colin C, Pujana MAG, Ross K, Magoffin D, Aronin N, Cascon A, Hayashida CY, Li C, Toledo SPA, Stiles CD, Familial Pheochromocytoma Consortium. Novel pheochromocytoma susceptibility loci identified by integrative genomics. *Cancer Res* 2005;65:9651–8.
- 33 Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE, Chocron ES, Lechleiter JD, Sass M, Aronin N, Schiavi F, Boaretto F, Opocher G, Toledo RA, Toledo SPA, Stiles C, Aguiar RCT, Dahia PLM. Germline mutations in *TMEM127* confer susceptibility to pheochromocytoma. *Nat Genet* 2010;42:229–33.
- 34 Schork NJ, Boehnke M, Terwilliger JD, Ott J. Two-trait-locus linkage analysis: a powerful strategy for mapping complex genetic traits. *Am J Hum Genet* 1993;53:1127–36.
- 35 Fishelson M, Geiger D. Exact genetic linkage computations for general pedigrees. *Bioinformatics* 2002;18(Suppl):S189–8.
- 36 Neumann RJ, Rice JP. Two-locus models of disease. *Genet Epidemiol* 1992;9:347–65.
- 37 Li W, Reich J. A complete enumeration and classification of two-locus disease models. *Hum Hered* 2000;50:334–9.
- 38 Hallgrímsdóttir IB, Yuster DS. A complete classification of epistatic two-locus models. *BMC Genet* 2008;9:17.
- 39 Madsen AM, Ottman R, Hodge SE. Causal models for investigating complex genetic disease: II. what causal models can tell us about penetrance for additive, heterogeneity, and multiplicative two-locus models. *Hum Hered* 2011;72:63–72.
- 40 Bansal V, Halpern AL, Axelrod N, Bafna V. An MCMC algorithm for haplotype assembly from whole-genome sequence data. *Genome Res* 2008;18:1336–46.
- 41 Aguiar D, Istrail S. HapCompass: a fast cycle basis algorithm for accurate haplotype assembly of sequence data. *J Comput Biol* 2012;19:577–90.
- 42 He D, Han B, Eskin E. Hap-seq: an optimal algorithm for haplotype phasing with imputation using sequencing data. *J Comput Biol* 2013;20:80–92.
- 43 Cullinane AR, Vilboux T, O'Brien K, Curry JA, Maynard DM, Carlson-Donohoe H, Ciccone C. NISC Comparative Sequencing Program Markello TC, Gunay-Aygun M, Huizing M, Gahl WA. Homozygosity mapping and whole-exome sequencing to detect *SLC45A2* and *G6PC3* mutations in a single patient with oculocutaneous albinism and neutropenia. *J Invest Dermatol* 2001;131:2017–25.
- 44 Zheng QY, Scarborough JD, Zheng Y, Yu H, Choi D, Gillespie PG. Digenic inheritance of deafness caused by 8J allele of myosin-VIIA and mutations in other Usher I genes. *Hum Mol Genet* 2012;21:2588–98.
- 45 Arnos KS, Welch KO, Tekin M, Norris VW, Blanton SH, Pandya A, Nance WE. A comparative analysis of the genetic epidemiology of deafness in the United States in two sets of pedigrees collected more than a century apart. *Am J Hum Genet* 2008;83:200–7.
- 46 Wilch E, Zhu M, Burkhart KB, Regier M, Elfenbein JL, Fisher RA, Friderici KH. Expression of *GJB2* and *GJB6* is reduced in a novel *DFNB1* allele. *Am J Hum Genet* 2006;79:174–9.
- 47 Vozzi D, Aspillou A, Athanasakis E, Berto A, Fabretto A, Licastro D, Külm M, Testa F, Trevisi P, Vahter M, Ziviello C, Martini A, Simonelli F, Banfi S, Gasparini P. Molecular epidemiology of Usher syndrome in Italy. *Mol Vis* 2011;17:1662–8.
- 48 Ahmed ZM, Riazuddin S, Aye S, Ali RA, Venselaar H, Anwar S, Belyantseva PP, Qasim M, Riazuddin S, Friedman TB. Gene structure and mutant alleles of *PCDH15*: nonsyndromic deafness *DFNB23* and type 1 Usher syndrome. *Hum Genet* 2008;124:215–23.
- 49 Schultz JM, Yang Y, Caride AJ, Filoteo AG, Penheiter AR, Lagziel A, Morell RJ, Mohiddin SA, Fananapazir L, Madeo AC, Penniston JT, Griffith AJ. Modification of human hearing loss by plasma-membrane calcium pump *PMCA2*. *N Engl J Med* 2005;352:1557–64.
- 50 Pallares-Ruiz N, Blanchet P, Mondain M, Claustres M, Roux A-F. A large deletion including most of *GJB6* in recessive non syndromic deafness: a digenic effect? *Eur J Hum Genet* 2002;10:72–6.

- 51 del Castillo I, Villamar M, Moreno-Pelayo MA, del Castillo FJ, Álvarez A, Tellería D, Menéndez I, Moreno F. A deletion involving the connexin 30 gene in nonsyndromic hearing impairment. *N Engl J Med* 2002;24:243–9.
- 52 del Castillo FJ, Rodríguez-Ballesteros M, Álvarez A, Hutchin T, Leonardi E, de Oliveira CA, Azaiez H, Brownstein Z, Avenarius MR, Marlin S, Pandya A, Shahin H, Siemerling KR, Weil D, Wuyts W, Aguirre LA, Martin Y, Moreno-Pelayo MA, Villamar M, Avraham KB, Dahl HH, Kanaan M, Nance WE, Petit C, Smith RJ, Van Camp G, Sartorato EL, Murgia A, Moreno F, del Castillo I. A novel deletion involving the connexin-30 gene, del(GJB6-d13s1854), found in trans with mutations in the GJB2 gene (connexin-26) in subjects with DFNB1 non-syndromic hearing impairment. *J Med Genet* 2005;42:588–94.
- 53 Liu X-Z, Yuan Y, Yan D, Ding EH, Ouyang XM, Fei Y, Tang W, Yuan H, Chang Q, Du LL, Zhang X, Wang G, Ahmad S, Kang DY, Lin X, Dai P. Digenic inheritance of non-syndromic deafness caused by mutations at the gap junction proteins Cx26 and Cx31. *Hum Genet* 2009;125:53–62.
- 54 Rodríguez-Paris J, Schrijver I. The digenic hypothesis unraveled: the GJB6 del (GJB6-D13S1830) mutation causes allele-specific loss of GJB2 expression in cis. *Biochem Biophys Res Commun* 2009;389:354–9.
- 55 Rodríguez-Paris J, Tamayo ML, Gelvez N, Schrijver I. Allele-specific impairment of GJB2 expression by GJB6 deletion del(GJB6-D13S1854). *PLoS ONE* 2011;6:e21665.
- 56 Saudou F. A “so cilia” network: cilia proteins start “social” networking. *J Clin Invest* 2012;122:1198–201.
- 57 Brugmann SA, Allen NC, James AW, Mekonnen Z, Madan E, Helms JA. A primary cilia-dependent etiology for midline facial disorders. *Hum Mol Genet* 2010;19:1577–92.
- 58 McCabe MJ, Gaston-Massuet C, Tziaferi V, Gregory LC, Alatzoglou KS, Signore M, Puelles E, Gerrelli D, Farooqi IS, Raza J, Walker J, Kavanaugh SI, Tsai P-S, Pitteloud N, Martínez-Barbera J-P, Dattani MT. Novel FGF8 mutations associated with recessive holoprosencephaly, craniofacial defects, and hypothalamo-pituitary dysfunction. *J Clin Endocrinol Metab* 2011;96:E1709–18.
- 59 Nachury MV, Loktev AV, Zhang Q, Westlake CJ, Peränen J, Merdes A, Slusarski DC, Scheller RH, Bazan JF, Sheffield VC, Jackson PK. A core complex of BBS proteins cooperates with the GTPase Rab8 to promote ciliary membrane biogenesis. *Cell* 2007;129:1201–13.
- 60 Seo S, Baye LM, Schulz NP, Beck JS, Zhang Q, Slusarski DC, Sheffield VC. BBS6, BBS10, and BBS12 form a complex with CCT/TRiC family chaperonins and mediate BBSome assembly. *Proc Natl Acad Sci USA* 2010;107:1488–93.
- 61 Katsanis N, Eichers ER, Ansley SJ, Lewis RA, Kayserili H, Hoskins BE, Scambler PJ, Beales PL, Lupski JR. BBS4 is a minor contributor to Bardet-Biedl syndrome and may also participate in triallelic inheritance. *Am J Hum Genet* 2002;71:22–9.
- 62 Beales PL, Badano JL, Ross AJ, Ansley SJ, Hoskins BE, Kirsten B, Mein CA, Froguel P, Scambler PJ, Lewis RA, Lupski JR, Katsanis N. Genetic interaction of BBS1 mutations with alleles at other BBS loci can result in non-Mendelian Bardet-Biedl syndrome. *Am J Hum Genet* 2003;72:1187–99.
- 63 Hichri H, Stoetzel C, Laurier V, Caron S, Sigaudy S, Sarda P, Hamel C, Martin-Coignard D, Gilles M, Leheup B, Holder M, Kaplan J, Bitoun P, Lacombe D, Verloes A, Bonneau D, Perrin-Schmitt F, Brandt C, Besancon A-F, Mandel J-L, Cossée M, Dollfus H. Testing for triallelism: analysis of six BBS genes in a Bardet-Biedl syndrome family cohort. *Eur J Hum Genet* 2005;13:607–16.
- 64 Badano JL, Leitch CC, Ansley SJ, May-Simera H, Lawson S, Lewis RA, Beales PL, Dietz HC, Fisher S, Katsanis N. Dissection of epistasis in oligogenic Bardet-Biedl syndrome. *Nature* 2006;439:326–30.
- 65 Lee JE, Silhavy JL, Zaki MS, Schroth J, Bielas SL, Marsh SE, Olvera J, Brancati F, Iannicelli M, Ikegami K, Schlossman AM, Merriman B, Attié-Bitach T, Logan CV, Glass IA, Cluckey A, Louie CM, Lee JH, Raynes HR, Rapin I, Castroviejo IP, Setou M, Barbot C, Boltshauser E, Nelson SF, Hildebrandt F, Johnson CA, Doherty DA, Valente EM, Gleeson JG. CEP41 is mutated in Joubert syndrome and is required for tubulin glutamylation at the cilium. *Nat Genet* 2012;44:193–9.
- 66 Rachel RA, May-Simera HL, Veleri S, Gotoh N, Choi BY, Murga-Zamalloa C, McIntyre JC, Marek J, Lopez I, Hackett AN, Zhang J, Brooks M, den Hollander AI, Beales PL, Li T, Jacobson SG, Sood R, Martens JR, Liu P, Friedman TB, Khanna H, Koenekoop RK, Kelley MW, Swaroop A. Combining Cep290 and Mks ciliopathy alleles in mice rescues sensory defects and restores ciliogenesis. *J Clin Invest* 2012;122:1233–45.
- 67 Thiel C, Kessler G, Giessl A, Dimmler A, Shalev SA, von der Haar S, Zenker M, Zahnleiter D, Stöss H, Beinder E, Jamra R, Abou, Ekici AB, Schröder-Kref N, Aigner T, Kirchner T, Reis A, Brandstätter JH, Rauch A. NEK1 mutations cause short-rib polydactyly syndrome type Majewski. *Am J Hum Genet* 2011;88:106–14.
- 68 Koziell A, Grech V, Hussain S, Lee G, Lenkkeri U, Tryggvason K, Scambler P. Genotype/phenotype correlations of NPHS1 and NPHS2 mutations in nephrotic syndrome advocate a functional inter-relationship in glomerular filtration. *Hum Mol Genet* 2002;11:379–88.
- 69 Dodé C, Teixeira L, Leveilliers J, Fouveaut C, Bouchard P, Kottler M-L, Lespinasse J, Lienhardt-Roussie A, Mathieu M, Moerman A, Morgan G, Murat A, Toubian J-E, Wolczynski S, Delpech M, Petit C, Young J, Hardelin J-P. Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. *PLoS Genet* 2006;2:e175.
- 70 Pitteloud N, Quinton R, Pearce S, Raivio T, Acierno J, Dwyer A, Plummer L, Hughes V, Seminara S, Cheng Y-Z, Li W-P, Maccolli G, Eliseenkova AV, Olsen SK, Ibrahim OA, Hayes FJ, Boepple P, Hall JE, Bouloux P, Mohammadi M, Crowley W Jr. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. *J Clin Invest* 2007;117:457–63.
- 71 Miraoui H, Dwyer AA, Sykiotis GP, Plummer L, Chung W, Feng B, Beenken A, Clarke J, Pers TH, Dworzynski P, Keefe K, Niedziela M, Raivio T, Crowley WF Jr, Seminara SB, Quinton R, Hughes VA, Kumanov P, Young J, Yialamas MA, Hall JE, Van Vliet G, Chanoine J-P, Rubenstein J, Mohammadi M, Tsai P-S, Sidis Y, Lage K, Pitteloud N. Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism. *Am J Hum Genet* 2013;92:725–43.
- 72 Riazuddin S, Castelein CM, Ahmed ZM, Lalwani AK, Mastroianni MA, Naz S, Smith TN, Liburd NA, Friedman TB, Griffith AJ, Riazuddin S, Wilcox ER. Dominant modifier DFNM1 suppresses recessive deafness DFNB26. *Nat Genet* 2000;26:431–4.
- 73 Knoblauch H, Müller-Myhsok B, Busjahn A, Ben Avi L, Bähring S, Baron H, Heath SC, Uhlmann R, Faulhaber HD, Shpitzen S, Aydin A, Reshef A, Rosenthal M, Eliav O, Mühl A, Lowe A, Schurr D, Harats D, Jeschke E, Friedlander Y, Schuster H, Luft FC, Leitersdorf E. A cholesterol-lowering gene maps to chromosome 13q. *Am J Hum Genet* 2000;66:157–66.
- 74 Al-Kateb H, Bähring S, Hoffmann K, Strauch K, Busjahn A, Nürnberg G, Jouma M, Bautz EK, Dresel HA, Luft FC. Mutation in the ARH gene and a chromosome 13q locus influence cholesterol levels in a new form of digenic-recessive familial hypercholesterolemia. *Circ Res* 2002;90:951–8.
- 75 Basit S, Wali A, Aziz A, Muhammad N, Jelani M, Ahmad W. Digenic inheritance of an autosomal recessive hypotrichosis in two consanguineous pedigrees. *Clin Genet* 2011;79:273–81.
- 76 Oprea GE, Kröber S, McWhorter ML, Rossoll W, Müller S, Krawczak M, Bassell GJ, Beattie CE, Wirth B. Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. *Science* 2008;320:524–7.
- 77 Qin M, Hayashi H, Oshima K, Tahira T, Hayashi K, Kondo H. Complexity of the genotype-phenotype correlation in familial exudative vitreoretinopathy with mutations in the LRP5 and/or FZD4 genes. *Hum Mutat* 2005;26:104–12.
- 78 Addis M, Meloni C, Tosetto E, Ceol M, Cristofaro R, Melis MA, Vercelloni P, Del Prete D, Marra G, Anglani F. An atypical Dent’s disease phenotype caused by co-inheritance of mutations at CLCN5 and OCRL genes. *Eur J Hum Genet* 2013;21:687–90.
- 79 Carlton VEH, Harris BZ, Puffenberger EG, Batta AK, Knisely AS, Robinson DL, Strauss KA, Schneider BL, Lim WA, Salen G, Morton DH, Bull LN. Complex inheritance of familial hypercholesterolemia with associated mutations in TJP2 and BAAT. *Nat Genet* 2003;34:91–6.
- 80 Ebermann I, Walger M, Scholl HPN, Issa P Charbel, Lüke C, Nürnberg G, Lang-Roth R, Becker C, Nürnberg P, Bolz HJ. Truncating mutation of the DFNB59 gene causes cochlear hearing impairment and central vestibular dysfunction. *Hum Mutat* 2007;28:571–7.
- 81 Shoemaker BA, Panchenko AR. Deciphering protein-protein interactions part I. experimental techniques and databases. *PLoS Comput Biol* 2007;3:e42.
- 82 Razick S, Maglaras G, Donaldson IM. iRefIndex: a consolidated protein interaction database with provenance. *BMC Bioinformatics* 2008;9:405.
- 83 Turner B, Razick S, Turinsky AL, Vlasblom J, Crowley EK, Cho E, Morrison K, Donaldson IM, Wodak SJ. iRefWeb: interactive analysis of consolidated protein interaction data and their supporting evidence. *Database* 2010;2010:baq023.
- 84 Stojmirović A, Yu Y-K. ppiTrim: constructing non-redundant and up-to-date interactomes. *Database* 2011;2011:bar036.
- 85 Glissen C, Hoischen A, Brunner HG, Veltman JA. Disease gene identification strategies for exome sequencing. *Eur J Hum Genet* 2012;20:490–7.
- 86 Lupski JR, Belmont JW, Boerwinkle E, Gibbs RA. Clan genomics and the complex architecture of human disease. *Cell* 2011;147:32–43.
- 87 Yang T, Vidarsson H, Rodrigo-Blomqvist S, Rosengren SS, Enerbäck S, Smith RJH. Transcriptional control of SLC26A4 is involved in Pendred syndrome and nonsyndromic enlargement of vestibular aqueduct (DFNB4). *Am J Hum Genet* 2007;80:1055–63.
- 88 Adato A, Kalinski H, Weil D, Chaib H, Korostishevsky M, Bonne-Tamir B. Possible interaction between USH1B and USH3 gene products as implied by apparent digenic recessive inheritance. *Am J Hum Genet* 1999;65:261–5.
- 89 Ebermann I, Phillips JB, Liebau MC, Koenekoop RK, Schermer B, Lopez I, Schäfer E, Roux A-F, Dafinger C, Bernd A, Zrenner E, Claustres M, Blanco B, Nürnberg G, Nürnberg P, Ruland R, Westerfield M, Benzing T, Bolz HJ. PDZD7 is a modifier of retinal disease and a contributor to digenic Usher syndrome. *J Clin Invest* 2010;120:1812–23.
- 90 Schlingmann KP, Konrad M, Jeck N, Waldegger P, Reinalter SC, Holder M, Seyberth HW, Waldegger S. Salt wasting and deafness resulting from mutations in two chloride channels. *N Engl J Med* 2004;350:1314–19.
- 91 Auricchio A, Griseri P, Carpentieri ML, Betsos N, Staiano A, Tozzi A, Priolo M, Thompson H, Boccardi R, Romeo G, Ballabio A, Ceccherini I. Double heterozygosity for a RET substitution interfering with splicing and an EDNRB

- missense mutation in Hirschsprung disease. *Am J Hum Genet* 1999; 64:1216–21.
- 92 Tang B, Xiong H, Sun P, Zhang Y, Wang D, Hu Z, Zhu Z, Ma H, Pan Q, Xia JH, Xia K, Zhang Z. Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. *Hum Mol Genet* 2006;15:1816–25.
 - 93 Vincent AL, Billingsley G, Buys Y, Levin AV, Priston M, Trope G, Williams-Lyn D, Héon E. Digenic inheritance of early-onset glaucoma: CYP1B1, a potential modifier gene. *Am J Hum Genet* 2002;70:448–60.
 - 94 Morell R, Spritz RA, Ho L, Pierpont J, Guo W, Friedman TB, Asher JH Jr. Apparent digenic inheritance of Waardenburg syndrome type 2 (WS2) and autosomal recessive ocular albinism (AROA). *Hum Mol Genet* 1997;6:659–64.
 - 95 Hutton SM, Spritz RA. A comprehensive genetic study of autosomal recessive ocular albinism in Caucasian patients. *Invest Ophthalmol Vis Sci* 2008;49:868–72.
 - 96 Floeth M, Bruckner-Tuderman L. Digenic junctional epidermolysis bullosa: mutations in COL17A1 and LAMB3 genes. *Am J Hum Genet* 1999;65:1530–7.
 - 97 Bolliger-Stucki B, Lord ST, Furlan M. Fibrinogen Milano XII: a dysfunctional variant containing 2 amino acid substitutions, A α R16C and γ G165R. *Blood* 2001;98:351–7.
 - 98 Pei Y, Paterson AD, Wang KR, He N, Hefferton D, Watnick T, Germino GG, Parfrey P, Somlo S, St George-Hyslop P. Bilineal disease and trans-heterozygotes in autosomal dominant polycystic kidney disease. *Am J Hum Genet* 2001;68:355–63.
 - 99 Font-Llitjós M, Jiménez-Vidal M, Biscaglia L, Di Perna M, de Sanctis L, Rousaud F, Zelante L, Palacín M, Nunes V. New insights into cystinuria: 40 new mutations, genotype-phenotype correlation, and digenic inheritance causing partial phenotype. *J Med Genet* 2005;42:58–68.
 - 100 Savage DB, Agostini M, Barroso I, Gurnell M, Luan J, Meirhaeghe A, Harding A-H, Ihrke G, Rajanayagam O, Soos MA, George S, Berger D, Thomas EL, Bell JD, Meeran K, Ross RJ, Vidal-Puig A, Wareham NJ, O'Rahilly S, Chatterjee VK, Schaefer AJ. Digenic inheritance of severe insulin resistance in a human pedigree. *Nat Genet* 2002;31:379–84.
 - 101 Shastri BS, Trese MT. Cosegregation of two unlinked mutant alleles in some cases of autosomal dominant familial exudative vitreoretinopathy. *Eur J Hum Genet* 2004;12:79–82.
 - 102 Berger M, Mattheisen M, Kulle B, Schmidt H, Oldenburg J, Bickeböller H, Walter U, Lindner TH, Strauch K, Schambeck CM. High factor VIII levels in venous thromboembolism show linkage to imprinted loci on chromosomes 5 and 11. *Blood* 2005;105:638–44.
 - 103 Meggouh F, de Visser M, Arts WFM, De Coe RIFM, van Schaik IN, Baas F. Early onset neuropathy in a compound form of Charcot-Marie-Tooth disease. *Ann Neurol* 2005;57:589–91.
 - 104 Hodapp JA, Carter GT, Lipe HP, Michelson SJ, Kraft GH, Bird TD. Double trouble in hereditary neuropathy: concomitant mutations in the PMP-22 gene and another gene produce novel phenotypes. *Arch Neurol* 2006;63:112–17.
 - 105 Vital A, Latour P, Sole G, Ferrer X, Rouanet M, Tison F, Vital C, Goizet C. A French family with Charcot-Marie-Tooth disease related to simultaneous heterozygous *MFN2* and *GDAP1* mutations. *Neuromuscul Disord* 2012;22:735–41.
 - 106 Muntoni F, Bonne G, Goldfarb LG, Mercuri E, Piercy RJ, Burke M, Yaou RB, Richard P, Récan D, Shatunov A, Sewry CA, Brown SC. Decreased severity in dominant Emery Dreifuss is increased by mutations in both emerin and desmin proteins. *Brain* 2006;129:1260–8.
 - 107 Santos M, Clevers HC, Marx JJ. Mutations of the hereditary hemochromatosis candidate gene HLA-H in porphyria cutanea tarda. *N Engl J Med* 1997;336:1327–8.
 - 108 Harraway JR, Florkowski CM, Sies C, George PM. Dual porphyria with mutations in both the UROD and HMBS genes. *Ann Clin Biochem* 2006;43:80–2.
 - 109 Akagi R, Inoue R, Muranaka S, Tahara T, Taketani S, Anderson KE, Phillips JD, Sassa S. Dual gene defects involving δ -aminolaevulinic acid dehydratase and coproporphyrinogen oxidase in a porphyria patient. *Br J Haematol* 2006;132:237–43.
 - 110 Baulac S, Picard F, Herman A, Feingold J, Genin E, Hirsch E, Prud'homme JF, Baulac M, Brice A, LeGuern E. Evidence for digenic inheritance in a family with both febrile convulsions and temporal lobe epilepsy implicating chromosome 18qter and 1q25-q31. *Ann Neurol* 2001;49:786–92.
 - 111 Merryweather-Clarke AT, Cadet E, Bomford A, Capron D, Viprakasit V, Miller A, McHugh PJ, Chapman RW, Poinson JJ, Wimbush V, Livesey KJ, Tanphaichitr V, Rochette J, Robson KJH. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. *Hum Mol Genet* 2003;12:2241–7.
 - 112 Van Goethem G, Löfgren A, Dermaut B, Ceuterick C, Martin J-J, Van Broeckhoven C. Digenic progressive external ophthalmoplegia in a sporadic patient: recessive mutations in *POLG* and *C10orf2/Twinkle*. *Hum Mutat* 2003;22:175–6.
 - 113 Ito M, Yamakawa K, Sugawara T, Hirose S, Fukuma G, Kaneko S. Phenotypes and genotypes in epilepsy with febrile seizures plus. *Epilepsy Res* 2006;70(Suppl 1): S199–205.
 - 114 Pinto D, Kasteleijn-Nolst Trenité DGA, Cordell HJ, Mattheisen M, Strauch K, Lindhout D, Koeleman BPC. Explorative two-locus linkage analysis suggests a multiplicative interaction between the 7q32 and 16p13 myoclonic seizures-related photosensitivity loci. *Genet Epidemiol* 2007;31:42–50.
 - 115 Naved M, Nath SK, Gaines M, Al-Ali MT, Al-Khaja N, Hutchings D, Golla J, Deutsch S, Bottani A, Antonarakis SE, Ratnamala U, Radhakrishna U. Genomewide linkage scan for split-hand/foot malformation with long-bone deficiency in a large Arab family identifies two novel susceptibility loci on chromosomes 1q42.2-q43 and 6q14.1. *Am J Hum Genet* 2007;80:105–11.
 - 116 Bröer S, Bailey CG, Kowalczyk S, Ng C, Vanslambrouck JM, Rodgers H, Auray-Blais C, Cavanaugh JA, Bröer A, Rasko JE. Iminoglycinuria and hyperglycinuria are discrete human phenotypes resulting from complex mutations in proline and glycine transporters. *J Clin Invest* 2008;118:3881–92.
 - 117 Burdon KP, Coster DJ, Charlesworth JC, Mills RA, Laurie KJ, Giunta C, Hewitt AW, Latimer P, Craig JE. Apparent autosomal dominant keratoconus in a large Australian pedigree accounted for by digenic inheritance of two novel loci. *Hum Genet* 2008;124:379–86.
 - 118 Trabelsi M, Kavian N, Daoud F, Commere V, Debrugrave N, Beugnet C, Lense S, Barbot JC, Vasson A, Kaplan JC, Leturcq F, Chelly J. Revised spectrum of mutations in sarcoglycanopathies. *Eur J Hum Genet* 2008;16:793–803.
 - 119 Nadeau A, Kinali M, Main M, Jimenez-Mallebrera C, Aloysius A, Clement E, North B, Manzur AY, Robb SA, Mercuri E, Muntoni F. Natural history of Ullrich congenital muscular dystrophy. *Neurology* 2009;73:25–31.
 - 120 Li Q, Grange DK, Armstrong NL, Whelan AJ, Hurley MY, Rishavy MA, Hallgren KW, Berkner KL, Schurgers LJ, Jiang Q, Uitto J. Mutations in the *GGCX* and *ABCC6* genes in a family with pseudoxanthoma elasticum-like phenotypes. *J Invest Dermatol* 2009;129:553–63.
 - 121 Brusse E, Majoor-Krakauer D, de Graaf BM, Visser GH, Swagemakers S, Boon AJ, Oostra BA, Bertoli-Avella AM. A novel 16p locus associated with BSCL2 hereditary motor neuronopathy: a genetic modifier? *Neurogenetics* 2009;10:289–97.
 - 122 Wang Y, Li X, Zhu W-L, Guo J-Z, Song X-M, Li S-Q, Li Y. Genome-wide and interaction linkage scan for nonsyndromic cleft lip with or without cleft palate in two multiplex families in Shengyang, China. *Biomed Env Sci* 2010;23: 363–73.
 - 123 Kelberman D, Islam L, Holder SE, Jacques TS, Calvas P, Hennekam RC, Nischal KK, Sowden JC. Digenic inheritance of mutations in *FOXC1* and *PITX2*: correlating transcription factor function and Axenfeld-Rieger disease severity. *Hum Mutat* 2011;32:1144–52.
 - 124 Morak M, Massdorf T, Sykora H, Kerscher M, Holinski-Feder E. First evidence for digenic inheritance in hereditary colorectal cancer by mutations in the base excision repair genes. *Eur J Cancer* 2011;47:1046–55.
 - 125 Padalon-Brauch G, Ben Amitai D, Vodo D, Harel A, Sarig O, Sprecher E, Mashiah J. Digenic inheritance in epidermolysis bullosa simplex. *J Invest Dermatol* 2012;132:2852–4.

Disease	Gene/Locus1	Inh.	Gene/Locus2	Inh.	Gene Interaction	Loci Linked	Pedigree evidence	Replication	Ref.
Long QT syndrome (LQTS)	<i>KCNH2</i> /7q	AD	<i>KCNQ1</i> /11p	AD	Protein-protein	No	Minimal	Yes	22
LQTS	various LQT genes	AD	various LQT genes	AD	Protein-protein	No	Yes	Yes	23-26
Deafness	<i>GJB2</i> /13q	AD	<i>GJB6</i> /13q	AD	Protein-protein	Yes	Yes	DNA level	9 50-52
Deafness	<i>GJB2</i> /13q	AD	<i>GJB3</i> /1p	AD	Protein-protein	No	Minimal	Of prior studies	53
Deafness	<i>TECTA</i> /11q	AD	1p	AD	NA	No	Yes	No	30 31
Pendred syndrome/deafness	<i>SLC26A4</i> /7q	AD	<i>FOXI1</i> /5q	AD	Protein-DNA	No	No	No	87
Deafness suppression	1q	AR	4q	AR	NA	No	Yes	No	72
Deafness	<i>CDH23</i> /10q	AR	<i>ATP2B2</i> /3p	AD	?	No	Yes	Partial	49
Usher syndrome	<i>MYO7A</i> /11q	AR	3q	AD	?	No	Minimal	No	88
Usher syndrome	<i>CDH23</i> /10q	AD	<i>PCDH15</i> /10q	AD	?	Yes	Yes	Yes	27
Usher syndrome	<i>CDH23</i> /10q	AD	<i>PCDH15</i> /10q	AD	?	Yes	No	Of prior study	S1
Usher syndrome	<i>PDZD7</i> /10q	variable	<i>GPR98</i> /5q	variable	Protein-protein	No	Yes	Internal	89
Bartter's syndrome (antenatal w/deafness)	<i>CLCNKA</i> /1p	AR	<i>CLCNKB</i> /1p	AR	Pathway	Yes	Minimal	Yes	90 S2
Bardet-Biedl syndrome	<i>BBS2</i> /16q	Triallelic	various BBS loci	triallelic	Protein-protein	No	Minimal	Yes	8
Bardet-Biedl syndrome	<i>BBS4</i> /15q	variable	various BBS genes	variable	Protein-protein	No	Minimal	Yes	61
Bardet-Biedl syndrome	<i>BBS1</i> /11q	variable	various BBS genes	variable	Protein-protein	No	Yes	Yes	62
Bardet-Biedl syndrome	various BBS genes	variable	various BBS genes	variable	Protein-protein	No	No	Of prior studies	S3
Bardet-Biedl syndrome	various BBS genes	AR	<i>CCDC28B</i> /1p	variable	Protein-protein	No	Minimal	Internal	64
Bardet-Biedl syndrome	<i>BBS7</i> /4q	AR	various BBS genes	AD	Protein-protein	No	Minimal	Of prior studies	S4
Bardet-Biedl syndrome (+ciliopathies)	various BBS genes	variable	various BBS genes	variable	Protein-protein	No	Minimal	Of prior studies	19
Bardet-Biedl syndrome	various BBS genes	triallelic	various BBS genes	triallelic	Protein-protein	No	Minimal	Of prior studies	20
Bardet-Biedl syndrome	various BBS genes	triallelic	various BBS genes	triallelic	Protein-protein	No	Not shown	Of prior studies	S5
Joubert syndrome (+ciliopathies)	<i>CEP41</i> /7q	AD	various genes	various	Pathway	No	No	No	65
Leber's congenital	<i>CEP290</i> /12q	AR	<i>MKKS</i> /BBS6/20p	AD	Protein-protein	No	No	Internal	66

amaurosis(+ciliopathies)									
Short-rib polydactyly (ciliopathy)	<i>NEK1</i> /4q	AD	<i>DYNC2H1</i> /11q	AD	Pathway	No	No	No	67
Nephrotic syndrome	<i>NPHS1</i> /19q	triallelic	<i>NPHS2</i> /1q	triallelic	Protein-protein	No	Minimal	Yes	68
Nephrotic syndrome	<i>NPHS1</i> /19q	triallelic	<i>NPHS2</i> /1q	triallelic	Protein--protein	No	Minimal	Of prior study	S6
Nephrotic syndrome	various genes	various	various genes	various	Protein-protein	No	Minimal	Of prior studies	S7
Hypogonadotropic hypogonadism	<i>PROKR2</i> /20p	AD	<i>KAL1</i> /Xp	XLR	No	No	Minimal	Yes	69
Hypogonadotropic hypogonadism	<i>FGFR1</i> /8p	AD	<i>NSMD</i> /9q	AD	No	No	Minimal	Yes	70
Hypogonadotropic hypogonadism	<i>PROKR2</i> /20p	AD	<i>KAL1</i> /Xp	XLR	No	No	Minimal	Of prior studies	S8
Hypogonadotropic hypogonadism	various HH genes	AD or triallelic	various HH genes	AD or triallelic	No	No	No	Yes	S9
Hypogonadotropic hypogonadism	<i>NSMD</i> /9q	AD	<i>KAL1</i> /Xp	XLR	No	No	No	Of prior studies	S10
Hypogonadotropic hypogonadism	<i>NSMD</i> /9q	AD	<i>TACR3</i> /4q	AD	No	No	No	Of prior studies	S10
Hypogonadotropic hypogonadism	<i>PROKR2</i> /20p	AD	<i>FGFR1</i> /8p	AD	No	No	No	Of prior studies	S11
Hypogonadotropic hypogonadism	<i>FGF8</i> -related	AD	<i>FGF8</i> -related	AD	Pathways	No	No	Internal	71
Hypogonadotropic hypo. (syndromic)	<i>RNF216</i> /7p	AR	<i>OTUD4</i> /4q	AD	Pathway	No	Yes	No	17
Hirschsprung disease	<i>RET</i> /10q	AD	<i>EDNRB</i> /13q	AD	Pathways?	No	Minimal	Yes	91
Hirschsprung disease	<i>RET</i> /10q	AD	<i>EDNRB</i> /13q	AD	Pathways?	No	Yes	Yes	S12
Hirschsprung disease	<i>RET</i> /10q	AD	<i>EDNRB</i> /EDN3	AD	Pathways?	No	Minimal	Of prior studies	S13
Parkinson's disease	<i>PARK7</i> /1p	AD	<i>PINK1</i> /1p	AD	Protein-protein	Yes	Minimal	No	92
Parkinson's disease	<i>PARKIN</i> /6q	AR	<i>PINK1</i> /1p	AD	Same pathway?	No	Minimal	No	S14
Retinitis pigmentosa	<i>PRPH2</i> /6p	AD	<i>ROM1</i> /11q	AD	Protein-protein	No	Yes	Internal	7
Glaucoma (earlier onset)	<i>MYOC</i> /1q	AD	<i>CYP11B1</i> /2p	AD	No	No	Yes	Yes	93
Waardenburg syndrome/albinism	<i>MITF</i> /3p	AD	<i>TYR</i> /11q	AD	Protein-DNA	No	Minimal	Partial	S15 94
Oculocutaneous albinism (OCA)	<i>TYR</i> /11q	triallelic	<i>OCA2</i> /15q	triallelic	Pathway	No	No	Partial	95
Oculocutaneous albinism (OCA)	three OCA genes	AD	three OCA genes	AD	Pathway	No	No	Internal	S16

Junctional epidermolysis bullosa	<i>COL17A1</i> /10q	AR	<i>LAMB3</i> /1q	AD	Protein-protein	No	No	No	96
Disfibrinogenemia (slow clotting)	<i>FGA</i> /4q	AD	<i>FGG</i> /4q	AD	Protein-protein	Yes	No	No	97
Polycystic kidney disease	<i>PKD1</i> /16p	AD	<i>PKD2</i> /4q	AD	Protein-protein	No	Yes	No	98
Holoprosencephaly	<i>SHH</i> /7q	AD	<i>TGIF1</i> /18p	AD	Pathway	No	Minimal	Internal	11
Holoprosencephaly	<i>SHH</i> /7q	AD	<i>ZIC2</i> /13q	AD	Pathway	No	Minimal	No	11
Familial hypercholest. suppression	<i>LDLR</i> /19p	AD	13q	AR	NA	No	Yes	No	73
High LDL	<i>LDLRAP1</i> /1p	AR	13q	AR	NA	No	Yes	Internal	64
Cystinuria	<i>SLC3A1</i> /2p	triallelic	<i>SLC7A9</i> /19q	triallelic	Protein-protein	No	Minimal	Yes	99
Cystinuria	<i>SLC3A1</i> /2p	triallelic	<i>SLC7A9</i> /19q	triallelic	Protein-protein	No	No	Of prior study	S17
Hyperinsulinemia	<i>PPARG</i> /3p	AD	<i>PPP1R3A</i> /7q	AD	No	No	Minimal	No	100
Hypercholanemia	<i>TJP2</i> /9q	AR	<i>BAAT</i> /9q	AD	No	Weakly	Yes	No	79
Pheochromocytoma	<i>TMEM127</i> /2q	AR*	16p	AR	NA	No	Yes	No	32 33
Familial exudative vitreoretinopathy(FEVR)	<i>FZD4</i> /11q	AD	<i>F5</i> /1q	AD	No	No	Minimal	No	101
Familial exudative vitreoretinopathy(FEVR)	<i>FZD4</i> /11q	AD	<i>LRP5</i> /11q	AD	Pathway	Yes	Minimal	No	77
Factor VIII thromboembolism	5q	optimized	11q	optimized	NA	No	Yes	No	102
PMP22-related neuropathies	<i>PMP22</i> /17p	AD	various genes	AD or XLR	No	No	Minimal	Partial	103 104
PMP22-related neuropathy	<i>PMP22</i> /17p	AD	<i>MPZ</i> /1q	AD	No	No	Minimal	Of prior study	S18
Charcot-Marie-Tooth disease (non-PMP22)	<i>MFN2</i> /1p	AD	<i>GDAP1</i> /8q	AD	No	No	Minimal	No	105
Emery-Dreifuss muscular dystrophy	<i>LMNA</i> /1q	AD	<i>EMD</i> /Xq	XLR	Protein-protein	No	Minimal	Yes	106
Emery-Dreifuss muscular dystrophy	<i>LMNA</i> /1q	AR	<i>EMD</i> /Xq	XLR	Protein-protein	No	Yes	Of prior study	S19
Porphyria (acute)	various genes	various	<i>HFE</i> /6p	AD	Pathway	No	No	At pathway level	107
Porphyria (acute)	<i>UROD</i> /1p	AD	<i>HMBS</i> /11q	AD	Pathway	No	No	At pathway level	108
Porphyria (acute)	<i>CPOX</i> /3q	AD	<i>ALAD</i> /9q	AD	Pathway	No	Minimal	At pathway level	109
Porphyria (acute)	<i>PPOX</i> /1q	AD	<i>CPOX</i> /3q	AD	Pathway	No	Minimal	Of prior studies	S20
Epilepsy w/febrile seizures	1q	AD	18q	AD	NA	No	Yes	No	110

Hemachromatosis	<i>HFE</i> /6p	various	<i>HAMP</i> /19q	AD	Pathway	No	Minimal	No	111
Progressive external ophthalmoplegia (PEO)	<i>C10orf2</i> /10q	AD	<i>POLG</i> /15q	AD	No	No	No	No	112
Epilepsy w/febrile seizures	<i>SCN1A</i> /2q	AD	<i>SCN2A</i> /2q	AD	No	Yes	Minimal	No	113
Photosensitivity in epilepsy	7q	optimized	16p	optimized	NA	No	Yes	No	114
Split-hand/foot malformation	1q	AD	6q	AD	NA	No	Yes	No	115
Iminoglycinuria	<i>SLC36A2</i> /5q	AR	<i>SLC6A20</i> /3p	AD	Pathway	No	Yes	Internal	116
Keratoconus	1p	AD	8q	AD	NA	No	Yes	No	117
Limb-girdle muscular dystrophy	<i>SGCB</i> /4q	AD	<i>SGCD</i> /5q	AD	Protein-protein	No	No	No	118
Ullrich congenital muscular dystrophy	<i>COL6A1</i> /21q	AD	<i>COL6A2</i> /21q	AD	Protein-protein	Yes	No	No	119
Pseudoxanthoma elasticum	<i>ABCC6</i> /16p	AD	<i>GGCX</i> /2p	AD	No	No	Minimal	No	120
Hereditary motor neuropathy	<i>DSCL2</i> /11q	AD	16p	AD	NA	No	Yes	No	121
Cleft lip	1q	AD	2p	AD	NA	No	Yes	No	122
Fuchs corneal dystrophy	<i>ZEB1</i> /10p	AD	9p	AD	NA	No	Yes	No	29
Axenfeld-Rieger syndrome	<i>PITX2</i> /4q	AD	<i>FOXC1</i> /6p	AD	Protein-protein	No	Minimal	No	123
Colorectal cancer	<i>MUTYH</i> /1p	AD	<i>OGG1</i> /3p	AD	Pathway	No	Minimal	No	124
Rotor syndrome (hyperbilirubinemia)	<i>SLCO1B1</i> /12p	AR	<i>SLCO1B3</i> /12p	AR	Pathway	Yes	Yes	Internal	28
Dent's disease	<i>CLCN5</i> /Xp	XLR	<i>OCRL</i> /Xq	XLR	Pathway?	Weakly	Minimal	No	78
Facioscapulohumeral muscular dystrophy type 2	<i>DUX4</i> /4q	AD	<i>SMCHD1</i> /18p	AD	Protein/DNA	No	Yes	Internal	16
Epidermolysis bullosa simplex	<i>KRT5</i> /12q	AD	<i>KRT14</i> /17q	AD	Protein-protein	No	Minimal	No	125
Melanoma susceptibility	<i>CDKN2A</i> /9p	AD	<i>MC1R</i> /16q	various	No	No	Yes	Yes	21 S21- S23
Hypotrichosis (nonsyndromic)	<i>CDH3</i> /16q	AR	12q	AR	NA	No	Yes	Internal	75
Cone rod dystrophy & deafness	<i>MERTK</i> /2q	AR	<i>DFNB59</i> /2q	AR	No, two diseases	Weakly	Yes	No	80
Oculocutaneous albinism & cytopenia	<i>SLC45A2</i> /5p	AR	<i>G6PC3</i> /17q	AR	No, two diseases	No	Minimal	No	43

Online Supplementary Table S1. This is an extended version of Table 1 with a catalog of publications of cases of human digenic inheritance. The extended version includes extra rows for multiple gene pairs in the same paper and for replication studies. The extended version includes extra columns to describe the mode of inheritance at each locus and whether the genes/proteins are known to interact. The possible modes of inheritance are: AD (autosomal dominant), AR (autosomal recessive), XLR (X-linked recessive), triallelic (two variant alleles in one gene and one variant allele in the other gene), or optimized (the penetrance function or other parameters used for genetic linkage analysis were determined by some numerical optimization procedure using at least some of the pedigree data as input). References with only numbers are in the References of the main document. References cited only in Table S1 are listed below it with indices S1 through S23.

References cited only in online supplementary table S1

- S1 Vozzi D, Aaspõllu A, Athanasakis E, Berto A, Fabretto A, Licastro D, Külm M, Testa F, Trevisi P, Vahter M, Ziviello C, Martini A, Simonelli F, Banfi S, Gasparini P. Molecular epidemiology of Usher syndrome in Italy. *Mol Vis* 2011;17:1662-8.
- S2 Nozu K, Inagaki T, Fu XJ, Nozu Y, Kaito H, Kanda K, Sekine T, Igarashi T, Nakanishi K, Yoshikawa N, Iijima K, Matsuo M. Molecular analysis of digenic inheritance in Bartter syndrome with sensorineural deafness. *J Med Genet* 2008;45:182-6.
- S3 Fauser S, Munz M, Besch D. Further support for digenic inheritance in Bardet-Biedl syndrome. *J Med Genet* 2003;40:e104.
- S4 Bin J, Madhavan J, Ferrini W, Mok CA, Billingsley G, Héon E. BBS7 and TTC8 (BBS8) mutations play a minor role in the mutational load of Bardet-Biedl syndrome in a multiethnic population. *Hum Mutat* 2009;30:E737-46.
- S5 Chen J, Smaoui N, Hammer MB, Jiao X, Riazuddin SA, Harper S, Katsanis N, Riazuddin S, Chaabouni H, Berson EL, Hejtmancik JF. Molecular analysis of Bardet-Biedl syndrome families: report of 21 novel mutations in 10 genes. *Invest Ophthalmol Vis Sci* 2011;52:5317-24.
- S6 Weber S, Gribouval O, Esquivel EL, Morinière V, Tête MJ, Legendre C, Niaudet P, Antignac C. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. *Kidney Int* 2004;66:571-9.
- S7 Löwik M, Levtchenko E, Westra D, Groenen P, Steenbergen E, Weening J, Lilien M, Monnens L, van den Heuvel L. Bigenic heterozygosity and the development of steroid-resistant focal segmental glomerulosclerosis. *Nephrol Dial Transplant* 2008;23:3146-51.
- S8 Canto P, Munguía P, Söderlund D, Castro JJ, Méndez JP. Genetic analysis in patients with Kallmann syndrome: coexistence of mutations in prokineticin receptor 2 and *KAL1*. *J Androl* 2009;30:41-5.
- S9 Sykiotis GP, Plummer L, Hughes VA, Au M, Durrani S, Nayak-Young S, Dwyer AA, Quinton R, Hall JE, Gusella JF, Seminara SB, Crowley WF Jr, Pitteloud N. Oligogenic basis of isolated gonadotropin-releasing hormone deficiency. *Proc Natl Acad Sci USA* 2010;107:15140-4.

- S10 Xu N, Kim H-G, Bhagavath B, Cho S-G, Lee JH, Ha K, Meliciani I, Wenzel W, Podolsky RH, Chorich LP, Stackhouse KA, Grove AMH, Odom LN, Ozata M, Bick DP, Sherins RJ, Kim S-H, Cameron RS, Layman LC. Nasal embryonic LHRH factor (NELF) mutations in patients with normosmic hypogonadotropic hypogonadism and Kallmann syndrome. *Fertil Steril* 2011;95:1613-20.
- S11 Avbelj Stefanija M, Jeanpierre M, Sykiotis GP, Young J, Quinton R, Abreu AP, Plummer L, Au MG, Balasubramanian R, Dwyer AA, Florez JC, Cheetham T, Pearce SH, Purushothaman R, Schinzel A, Pugeat M, Jacobson-Dickman EE, Ten S, Latronico AC, Gusella JF, Dode C, Crowley WF Jr, Pitteloud N. *Hum Mol Genet* 2012;21:4314-24.
- S12 Carrasquillo MM, McCallion AS, Puffenberger EG, Kashuk CS, Nouri N, Chakravarti A. Genome-wide association study and mouse model identify interaction between RET and EDNRB pathways in Hirschsprung disease. *Nat Genet* 2002;32:237-44.
- S13 Garcia-Barceló M, Sham MH, Lee WS, Lui VC, Chen BL, Wong KK, Wong JS, Tam PK. Highly recurrent RET mutations and novel mutations in genes of the receptor tyrosine kinase and Endothelin Receptor B pathways in Chinese patients with sporadic Hirschsprung disease. *Clin Chem* 2004;50:93-100.
- S14 Funayama M, Li Y, Tsoi TH, Lam CW, Ohi T, Yazawa S, Uyama E, Djaldetti R, Melamed E, Yoshino H, Imamichi Y, Takashima H, Nishioka K, Sato K, Tomiyama H, Kubo S, Mizuno Y, Hattori N. Familial Parkinsonism with digenic *Parkin* and *PINK1* mutations. *Mov Disord* 2008;23:1461-5.
- S15 Kaur K, Reddy ABM, Mukhopadhyay A, Mandal AK, Hasnain SE, Ray K, Thomas R, Balasubramanian D, Chakrabarti S. Myocilin gene implicated in primary congenital glaucoma. *Clin Genet* 2005;67:335-40.
- S16 Wei AH, Yang XM, Lian S, Li W. Genetic analyses of Chinese patients with digenic oculocutaneous albinism. *Chin Med J* 2013;126:226-30.
- S17 Gucev Z, Ristoska-Bojkovska N, Popovska-Jankovic K, Sukarova-Stefanovska E, Tasic V, Plaseska-Karanfilska D, Efremov GD. Cystinuria AA (B): digenic inheritance with three mutations in two cystinuria genes. *J Genet* 2011;90:157-9.
- S18 Young T, Shuey N, Partridge J, Bremner FD, Nicholl DJ. Compound Charcot-Marie-Tooth disease: a kindred with severe hereditary neuropathy, pupil abnormalities and a novel MPZ mutation. *J Neurol Neurosurg Psychiatry* 2013;84:234-6.

- S19 Ben Yaou R, Toutain A, Arimura T, Demay L, Massart C, Peccate C, Muchir A, Llense S, Deburgrave N, Leturcq F, Litim KE, Rahmoun-Chiali N, Richard P, Babuty D, Récan-Budiarta D, Bonne G. Multitissular involvement in a family with *LMNA* and *EMD* mutations: Role of digenic mechanism? *Neurology* 2007;68:1883-94.
- S20 van Tuyll van Serooskerken AM, de Rooij FW, Edixhoven A, Bladergroen RS, Baron JM, Joussen S, Merk HF, Steijlen PM, Poblete-Gutiérrez P, te Velde K, Wilson JHP, Koole RH, van Geel M, Frank J. Digenic inheritance of mutations in the *coproporphyrinogen oxidase* and *protoporphyrinogen oxidase* genes in a unique type of porphyria. *J Invest Dermatol* 2011;131:2249-54.
- S21 Peris K, Fargnoli MC, Pacifico A, Surrenti T, Stolz W, Wolf P, Soyer HP, Chimenti S. *CDKN2A* and *MC1R* mutations in patients with sporadic multiple primary melanoma. *J Invest Dermatol* 2004;122:1327-1330.
- S22 Demenais F, Mohamdi H, Chaudru V, Goldstein AM, Newton Bishop JA, Bishop DT, Kanetsky PA, Hayward NK, Gillanders E, Elder DE, Avril MF, Azizi E, van Belle P, Bergman W, Bianchi-Scarrà G, Bressac-de Paillerets B, Calista D, Carrera C, Hansson J, Harland M, Hogg D, Höiom V, Holland EA, Ingvar C, Landi MT, Lang JM, Mackie RM, Mann GJ, Ming ME, Njauw CJ, Olsson H, Palmer J, Pastorino L, Puig S, Randerson-Moor J, Stark M, Tsao H, Tucker MA, van der Velden P, Yang XR, Gruis N; Melanoma Genetics Consortium. Association of *MC1R* variants and host phenotypes with melanoma risk in *CDKN2A* mutation carriers: a GenoMEL study. *J Natl Cancer Inst* 2010;102:1568-83.
- S23 Helsing P, Nymoen DA, Rootwelt H, Vårdal M, Akslen LA, Molven A, Andresen PA. *MC1R*, *ASIP*, *TYR*, and *TYRP1* gene variants in a population-based series of multiple primary melanomas. *Genes Chromosomes Cancer* 2012;51:654-61.